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ABSTRACT 
 
Alexandra Jazz Dickinson: Single-Cell Analysis of Lipid Enzyme Activity Using Automated 
Capillary Electrophoresis 
(Under the direction of Nancy L. Allbritton) 
 
 
 
Lipid enzymes play critical roles in regulating the function and behavior of cells. 
Dysregulation of lipid enzymes is an important factor in a variety of diseases. For instance, 
sphingosine kinase is a crucial regulator of cell proliferation, survival, and differentiation. 
Phospholipase C is another key lipid enzyme that modulates proliferation, differentiation, and 
cytokinesis. Aberrant activity of both enzymes has been implicated in diseases involving the 
immune system, including leukemic, inflammatory, and autoimmune diseases. However, very 
little is known about the activity of these enzymes at the single-cell level, although cellular 
heterogeneity is a characteristic feature of the immune system and of many immune system 
diseases. In fact, assays typically used to directly measure lipid enzyme activity require bulk cell 
lysates comprised of thousands of cells. Therefore, the development of a technology capable of 
measuring lipid enzyme activity in single cells may be essential in further elucidating the role of 
lipid enzymes in both normal and aberrant immune cell biology. 
Capillary electrophoresis (CE) is a powerful tool for single-cell analysis, but use of CE 
for single-cell applications has been limited by low throughput. Typically, the rate of single-cell 
CE is limited to 1 – 2 cells per hour. This dissertation will describe the development and 
characterization of a single-cell CE system capable of performing single-cell analysis at rates as 
high as 3.5 cells/min. The system was used to characterize sphingosine kinase activity in 
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hundreds of tissue-cultured cells derived from myeloid leukemia. Sphingosine kinase activity 
was additionally analyzed in primary leukemic cells from patients with different types of 
leukemia, including the deadliest form of leukemia, acute myeloid leukemia. The automated CE 
system was further used to characterize the sphingosine kinase pathway in primary natural killer 
cells from healthy subjects. Finally, a method for blocking lipid adsorption to device surfaces 
was developed to enable coupling of single-cell sphingosine kinase and phospholipase C activity 
measurements to immunofluorescence microscopy. In addition to the lipid enzyme activity 
measurements presented in this work, automated single-cell CE has the potential to analyze a 
variety of biomolecules and cell types for a broad range of biological applications.  
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This work is dedicated to Andrew, Torry, Robert, and Jeffree. Thank you for your 
constant support and love. 
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CHAPTER 1: INTRODUCTION 
 
1.1 The Role of Lipid Enzymes in Disease 
1.1.1 Enzymes and Enzyme Functions  
Enzymes are biological molecules responsible for catalyzing hundreds of cellular 
reactions that lead to processes such as movement, energy production, and metabolism. There are 
many types of enzymes with a diverse range of functions. For instance, protein kinases transmit 
intracellular and extracellular signals through a process called phosphorylation, the transfer of a 
phosphoryl moiety to an acceptor molecule, such as a protein or a lipid. The addition of a 
negatively charged phosphoryl group changes a substrate’s electrostatic properties and can 
change its conformation. This in turn can alter the substrate’s cellular localization, activity, or 
function.1 Phosphatases are enzymes responsible for dephosphorylating substrates by catalyzing 
the removal of a phosphoryl group by hydrolysis. Cell signaling networks that control vital cell 
processes, such as growth and survival, are activated through rapid exchange of phosphoryl 
groups by kinases and phosphatases. Aberrant regulation of kinases and phosphatases plays an 
important role in many diseases, including those involving dysregulation of the immune system. 
For example, kinases that control cell proliferation, differentiation, and survival, are found to be 
upregulated in multiple types of leukemia.2,3 Many FDA-approved chemotherapeutics for 
leukemia work by inhibiting kinases or other enzymes.4 Imatinib, a drug that inhibits 
constitutively active Abelson tyrosine kinase (Abl) in chronic myelogenous leukemia (CML), 
has been one of the most successful chemotherapeutics; it has increased the levels of therapeutic 
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response from 35% to 87% compared to the previous gold-standard treatments.5 In addition to 
FDA-approved medications, there are many kinase and phosphatase inhibitors being tested in 
clinical and preclinical trials as potential therapeutics for leukemia,6 multiple sclerosis,7 arthritis,8 
asthma,9 and other immune disorders.10,11  
1.1.2 Sphingosine Kinase  
The sphingosine kinase (SK) pathway is comprised of enzymes that regulate lipid 
metabolism and play an important role in cell proliferation, migration, and survival (Figure 
1.1).12 De novo sphingolipid synthesis starts with the catalysis of a decarboxylative condensation 
between serine and palmitoyl coenzyme A by serine palmitoyl transferase, forming 3-
ketodihydrosphingosine. This compound is reduced to dihydrosphingosine, which is then 
acetylated to dihydroceramide. Upon desaturation, dihydroceramide is converted to ceramide, 
which can be subsequently metabolized to a number of compounds, including sphingosine, a 
lipid second messenger. Sphingosine is formed by the hydrolysis of ceramide by ceramidase 
(CDase), and can be reconverted to ceramide by ceramide synthase (CerS), which acetylates 
sphingosine at the amino group. SK phosphorylates sphingosine to sphingosine-1-phosphate 
(S1P), which can be dephosphorylated back to sphingosine by S1P phosphatase (S1PP). S1P can 
also be irreversibly degraded into hexadecenal and ethanolamine phosphate (EP) by S1P lyase 
(S1PL). Hexadecenal is oxidized to hexadecenoic acid by fatty aldehyde dehydrogenase 
(FALDH) and is eventually reduced to palmitate and converted to a number of glycerolipids. 
There are many disorders that result from dysregulation of this pathway. For instance, Sjögren-
Larsson syndrome, which causes spastic paraplegia and mental retardation, is caused by 
mutations in FALDH that result in toxic accumulation of hexadecenal.13 This dissertation will 
focus specifically on the role of the SK pathway in diseases of the immune system. 
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 Sphingosine and ceramide are both pro-apoptotic signaling molecules that impede cell 
growth and survival.14 Sphingosine and ceramide regulate signal transduction pathways, such as 
the protein kinase C (PKC) pathway and the caspase pathway, respectively, to induce growth 
arrest, apoptosis, and senescence. S1P counteracts the effects of sphingosine and ceramide, 
stimulating signaling proteins, such as extracellular signal-regulated kinase (ERK), that promote 
cell growth and survival.15 The balance between sphingosine and S1P, mediated by SK, is 
therefore crucial in determining cell fate. Indeed, upregulated SK activity has been linked to 
increased tumor growth and invasiveness, and to reduced survival in a number of cancers, 
including leukemias and lymphomas.16,17 Increased SK activity has also been linked to drug 
resistance in leukemia and inhibitors of SK have been shown to increase leukemic cell death, 
even in multi-drug resistant cell lines.18,19 SK activity is upregulated in multiple types of 
leukemia, and a number of SK inhibitors are in pre-clinical and clinical trials as 
chemotherapeutics.20 Other drugs that shift the balance of the SK pathway, such as sphingosine 
and ceramide analogues, have shown promise in arresting tumor growth.21 The SK pathway is 
therefore a very promising chemotherapeutic target for preventing tumor progression and the 
development of drug resistance in leukemia.  
 The SK pathway is also an important regulator of the innate and adaptive immune 
response. Extracellular receptors for S1P (S1PR) play a major role in the trafficking of 
leukocytes, including T cells, B cells, mast cells, and natural killer (NK) cells.22 These 
leukocytes facilitate immune defenses by recruiting other immune cells and by attacking 
pathogens and cancerous cells.23 S1P is an important leukocyte chemoattractant, with the ability 
to both direct cell migration and affect leukocyte activity. For example, a member of the S1PR 
family is required for egress of NK cells to sites of inflammation,24 and extracellular S1P has 
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been reported to inhibit NK cell cytotoxicity.25 Therefore, modulating the activity of the SK 
pathway is a powerful strategy to tune the immune response. Additionally, the SK pathway is 
dysregulated in a number of immune system disorders, making the pathway a promising 
therapeutic target for many immune system diseases. For instance, an S1PR inhibitor is currently 
used to treat multiple sclerosis, a disorder where immune cells attack the central nervous 
system.26 This inhibitor works by blocking lymphocyte egress from the thymus and other 
lymphoid tissues, thereby preventing lymphocytes from infiltrating the central nervous system. 
Increased S1P levels lead to inflammation and inhibitors of SK have been shown to decrease 
inflammation in asthma, as well as other inflammatory diseases.27,28 Upregulated SK activity was 
even found to link inflammatory bowel disease with colitis-associated cancer by maintaining a 
signaling loop that constitutively stimulated oncogenic proteins.29 Determining how 
perturbations to the SK pathway affect immune cells may yield insights into treatment options 
for inflammatory disorders such as asthma, arthritis, and sepsis. 
1.1.3 Phospholipase C 
Phosphoinositides are key lipid regulators of many cellular processes, including 
differentiation, proliferation, survival, and migration.30 Phospholipase C (PLC) is an enzyme that 
irreversibly hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) 
and inositol triphosphate (IP3) (Figure 1.2A).
31 This particular step in the phosphoinositide 
pathway is important for regulating vital cell processes, including those upregulated in leukemia. 
PIP2, DAG and IP3 are all essential biomolecules, each of which has a variety of functions. PIP2 
modulates membrane trafficking, cytoskeletal remodeling, and cytokinesis.32 For example, PIP2 
controls growth factor receptor endocytosis and positively regulates potassium and calcium 
channels.33 PIP2 also stimulates actin polymerization by modulating the activity of a number of 
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actin regulatory proteins, such as cofilin, which is a major determinant of metastasis in breast 
cancer.34 PIP2 can be phosphorylated or dephosphorylated by multiple enzymes, generating 
phosphoinositides important for a number of regulatory processes, including those that 
frequently contribute to cancer development (Figure 1.2b). DAG is a second messenger that is 
predominantly recognized as an activator of PKC, although it also activates a number of other 
proteins, including guanine nucleotide exchange factors (GEFs) and guanosine triphosphatase 
activating proteins (GAPs).35 These proteins all regulate proliferation, differentiation, and 
cytoskeletal reorganization and are potential therapeutic targets in cancer.36,37 IP3 initiates the 
release of intracellular calcium from the endoplasmic reticulum. Calcium is a versatile signaling 
molecule and is a major second messenger critical for many cellular functions.38 Calcium-
mediated signaling has been implicated in the induction of differentiation in leukemic progenitor 
cells.39  
The conversion of PIP2 to DAG and IP3 is normally very tightly regulated, and 
imbalances in the PLC pathway are implicated in a number of diseases, including cancer.40,41 In 
fact, PLC has been studied extensively as a potential chemotherapeutic target. PLC can be 
activated by more than 100 different cell-surface receptors, including many growth factor 
receptors such as epidermal growth factor receptor (EGFR) and platelet-derived growth factor 
receptor (PDGFR).42 Growth factor receptors have been implicated in promoting tumor 
progression in a wide range of cancers; often more than one receptor is upregulated in a single 
tumor, making identifying and targeting receptors of interest difficult.43 In addition, targeting one 
growth factor receptor may cause the tumor to upregulate a different receptor in response, which 
can cause chemotherapeutic resistance. Targeting PLC is a promising alternative because it is a 
convergence point for many receptors. In fact, inhibiting PLC has been shown to decrease 
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invasiveness in four cancer cell lines, each of which had upregulated EGFR, PDGFR, human 
epidermal growth factor receptor (HER), or insulin-like growth factor receptor (IGF-1R), 
respectively.44 Targeting PLC in cancer has the additional advantage of inhibiting the conversion 
of PIP2 to DAG and therefore decreasing PKC activation. This could be beneficial because PKC 
promotes cell growth and is upregulated in cancers, including leukemia.45 PLC has been 
implicated in tumor progression, and specifically linked to increased cancer cell motility and 
metastasis, suggesting that targeting PLC may be an effective way to treat certain types of 
cancer.46 However, PLC has also been shown to act as a tumor suppressor in certain types of 
leukemia, indicating the role of PLC in cancer is complex. Further studies are needed to unravel 
whether targeting the PLC pathway would be effective in treating leukemia.  
 
1.2 Benefits of Single-Cell Enzyme Measurements 
In order to better understand the role of key lipid enzymes such as SK and PLC in 
immune system disorders, it is important to understand their functions at the single-cell level. 
Traditional assays for measuring SK and PLC enzyme activity perform measurements using bulk 
lysates composed of thousands of cells. These ensemble measurements often obscure precious 
information that can contribute to a better understanding of disease. This is because there is 
incredible heterogeneity between cells. In fact, it is becoming increasingly apparent that even 
genetically identical cells of the same type in the same tissue function with extraordinary 
heterogeneity. This heterogeneity can result from variations in enzyme expression and activity. 
The following section describes examples of this heterogeneity in immune cells and details the 
advantages of single-cell analysis for measuring lipid enzyme activity. 
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1.2.1 Heterogeneity in the Immune Response  
There are many reasons why enzyme activity varies between genetically identical cells. 
For example, differentiation is a major contributor to cellular heterogeneity. During 
differentiation, a less specialized cell, such as a stem cell, matures to become more functionally 
specific. In the immune system, hematopoietic stem cells have the ability to self-renew or to 
differentiate into all the blood cell lineages. They are the common precursor to red blood cells, 
leukocytes, and lymphocytes.47 Differentiating hematopoietic stem cells commit to a lineage by 
maturing into either common lymphoid or myeloid progenitors.48 Lymphoid progenitors can 
subsequently differentiate into B cells, T cells, or NK cells, while myeloid progenitors can 
eventually differentiate into granulocytes, platelets, and erythrocytes.49 These cells all have 
heterogeneous functions and protein expression profiles. For instance, the expression of CD38, 
an enzyme that promotes cell-cell adhesion, is high in hematopoietic progenitors, decreases as 
they mature into lymphocytes, and then increases again during cell activation.50 In addition to 
differentiation, immune cell heterogeneity can arise from the inherently stochastic nature of 
biochemical processes as well as to variations in the local environment surrounding cells. 
Immune cells are all exposed to slightly different microenvironments, giving each cell a distinct 
history of past encounters with different types of cells and biological molecules.51-53 Immune 
cells respond to their respective molecular interactions in ways that alter protein expression and 
activity, creating physiological variations between cells of the same type.53,54 In fact, even 
hematopoietic stem cells are a heterogeneous population of cells, in terms of their self-renewing 
potential, lifespan, method of differentiation, lineage bias, and protein expression.47,55,56 Another 
example of a heterogeneous immune cell type is NK cells. Recent analysis of protein expression 
in NK cells predicts that there are between 6,000 to 30,000 distinct subtypes of NK cells per 
 8 
person.57,58 These variations in protein expression can affect whether NK cells produce 
cytotoxins, which destroy infected and cancerous cells, or cytokines, which regulate the 
migration of other immune cells. This vast degree of heterogeneity of protein expression and 
function is not exclusive to NK cells. It is very likely that each individual immune cell has its 
own unique and distinctive characteristics.59 The challenge is then identifying and measuring 
these characteristics, such as enzymatic activity at the single-cell level, which are important for 
immune cell function and disease progression. For instance, single-cell variations in p38 
mitogen-activated protein kinase (MAPK) activity have been shown to affect which 
chemoattractants neutrophils prefer to respond to, which could have an important effect on 
inflammation in diseases such as asthma.60 It will be important to identify variations in the 
activity of many critical lipid enzymes, including SK and PLC, in order to fully understand their 
role in regulating diseases of the immune system.  
1.2.2 Heterogeneity in Leukemia  
Cellular heterogeneity is especially pronounced in certain diseases and is a characteristic 
feature of cancer.61 Tumor biopsy samples taken from different regions of the same tumor can 
have drastic variations in enzyme activity, gene expression, genetic mutations, allelic 
composition, and ploidy levels.62 This suggests that a patient could receive very different 
treatments and prognoses depending on which cells of the tumor were analyzed. This could 
result in a number of problems, including improper treatment and the development of drug 
resistance. In acute myeloid leukemia (AML), the deadliest form of leukemia,63 there is 
significant heterogeneity that derives in part from a leukemic stem cell (LSC) heirarchy.64 LSCs 
are a small population of cancerous cells that are analogous to hematopoietic stem cells in that 
they are capable of self-renewal and differentiation. These cells were identified by implanting 
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AML cells into immunologically deficient mice.65 In this experiment, the majority of leukemic 
cells were not capable of repopulating mice with all lineages of the original tumor. However, a 
subset of cells expressing CD34, a surface marker for hematopoietic progenitor cells, restored 
the same types of original leukemic blasts in the new host. Subsequent research has provided 
additional evidence that a differentiation-based hierarchical structure is present in AML, as well 
as other cancers.66,67 This mechanism of tumor initiation is important for disease treatment 
because as leukemic cells mature, they have limited capacity for proliferation and 
differentiation.64 This suggests that focusing chemotherapy on mature cells might temporarily 
delay tumor progression, but that targeting the LSC population may be the only way to 
permanently eliminate the entire population of cancer cells. In fact, it is suspected that relapse in 
AML patients is aggressive because LSCs have higher chemotherapeutic resistance due to their 
slow turnover rate and expression of membrane transporter proteins, including multidrug 
resistant protein (MDR-1).68,69 Therefore, specifically targeting the LSC subpopulation would 
have a profound impact on AML treatment. 
In addition to an LSC-based hierarchy, leukemic cells are especially prone to increased 
heterogeneity as a result of genetic mutations and clonal evolution.70-72 To further complicate the 
situation, these processes can occur with or without the presence of differentiation-based 
hierarchical heterogeneity. Darwinian-like clonal evolution occurs when one or more leukemic 
cells develop adaptations that increase their capability to survive and proliferate.73 These survival 
traits perpetuate and continue to evolve, and subsequent generations of leukemic cells become 
increasingly abnormal and heterogeneous. Chemotherapeutic treatments that are not directed at 
all subpopulations of a tumor have even been shown to galvanize this evolutionary process in 
leukemia.74 For example, imatinib, which competitively binds to the ATP-binding pocket of 
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breakpoint cluster region (Bcr) – Abl fusion protein (Bcr-Abl) activity, is very effective at killing 
the vast majority of leukemic cells with upregulated Bcr-Abl activity in patients with CML. 
However, small populations of cells have mutations that distort the normal conformation of the 
ATP-binding pocket of Bcr-Abl.75 This impairs the ability of imatinib to bind to its target and 
enables these mutated cells to continue to evolve and proliferate in the presence of imatinib. 
Over time, the tumor can be repopulated with highly imatinib-resistant leukemic cells. This 
demonstrates how important understanding intra-tumor heterogeneity is in diagnosing and 
treating leukemia. Each individual leukemic cell may have different pathways that are 
upregulated to induce the cell to proliferate and survive; in effect, each cell may have a slightly 
different disease. It will be critical to analyze leukemic tumors at the single-cell level and 
account for their heterogeneity in order to develop effective treatments and to prevent the 
development of drug resistance. 
1.2.3 Measurements in Complex Samples 
 Developing the capability to perform single-cell analysis is important for measuring 
intra-tumor heterogeneity, but an additional advantage is that it also provides a method for 
targeting cells of interest in complex samples. Immortalized cell lines have been used extensively 
to study enzymatic pathways in cells derived from the immune system.76 Although these cell 
lines are convenient and have revealed important biological information, there is increasing 
evidence that they deviate from primary cells in terms of enzyme activity, function, and 
behavior.77 For instance, a study found that there was no correlation between the multidrug 
resistance transcriptomes of primary and cultured leukemic cells. 78 In fact, cultured leukemic 
cells were actually more closely related to cultured colon cells than primary leukemic cells. 
Therefore, the most physiologically relevant system for studying immune or leukemic cell 
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biology is primary human cells. However, any specific type of primary human cell must be 
isolated from both tissue and other cell types before it can be analyzed. To analyze a population 
of primary leukemic cells, for example, blood must be separated into red blood cells and 
mononuclear cells.79 Leukemic blasts must then be purified from a mixed population that 
includes normal leukocytes and lymphocytes before they can be analyzed. Each of these steps 
takes place outside of the human body and subjects cells to various lengthy treatments that can 
perturb their biology. Ideally, enzyme activity would be measured in primary cells with as few 
perturbations as possible. Single-cell analysis enables this type of measurement because 
individual cells can be identified and examined independently without the added separation 
steps, even if the cells are in a mixed population. 
 Single-cell analysis also provides a method for measuring rare cell subpopulations. LSCs, 
for instance, only constitute 0.0001 – 0.1% of total AML blasts.80 Performing any type of 
traditional ensemble measurement dilutes the LSC signal severely. For example, standard 
enzyme activity assays, such as western blots, require hundreds of thousands of cells, which 
would completely obscure the activity of LSC enzymes.81 In fact, the main challenges in the 
study of LSC biology have been the low numbers of LSCs that can be isolated from AML 
patients, as well as the heterogeneity of LSC phenotypes and biological processes within each 
individual patient.80 A technique capable of measuring biological processes within AML cells 
with single-cell resolution could potentially address these challenges. A method for single-cell 
characterization of key enzymes, such as SK and PLC, could provide information enabling the 
targeting of LSCs for treating leukemia. It could also provide a way to measure these enzymes in 
other rare and heterogeneous cell populations that are critical to diseases of the immune system. 
 
 12 
1.3 Assays for Measuring Lipid Enzyme Activity 
1.3.1 Chromatography 
 The first measurements of SK activity were performed using thin-layer chromatography 
(TLC). In these assays, cells were lysed, the lysate was incubated with an excess of sphingosine 
and [32P] adenosine triphosphate (ATP), and the radio-labeled S1P was separated using TLC and 
detected.82 TLC has also been used to measure production of DAG as a proxy for PLC activity.83 
In this case, DAG was not radio-labeled, but was detected using a charring reagent. These TLC 
assays for SK and PLC activity were both performed by adding an excess of substrate. This 
enabled calculation of the ratio of product to substrate, a direct measure of enzyme activity. 
However, the amounts of natural substrates present in the reactions were not measured, which 
introduced unknown levels of error into these calculations. This suggests that these methods are 
not necessarily capable of directly quantifying physiological enzyme activity. Another major 
problem with TLC analysis is that the limit of detection (LOD) is much too high (nanomoles) for 
analysis of single-cells, which requires subattomole detection limits.  
 Another chromatographic technique that has been used to characterize lipid enzyme 
activity is high-performance liquid chromatography (HPLC). HPLC has higher resolution (the 
ability to separate compounds), peak capacities (the maximum number of compounds that can be 
separated), and lower detection limits than TLC (femtomoles vs nanomoles). In addition, HPLC 
has been used to separate fluorescently-labeled and endogenous sphingosine from S1P and detect 
the compounds using fluorescence or mass spectrometry (MS) techniques.84,85 HPLC has been 
used much less extensively to quantify PLC activity, although it has been used to separate PIP2 
from other anionic phospholipids.86 The LODs that can be achieved using HPLC, although lower 
than those in TLC, are still orders of magnitude too high to perform single-cell analysis. 
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1.3.2 Gene and Protein Expression 
 Many studies of SK and PLC have utilized measurements of biological molecules or 
processes that indirectly reflect enzyme activity. For instance, studies have measured gene and 
protein expression as proxies for SK activity.87-89 Others have manipulated SK gene expression, 
usually by creating knockout mice or by using siRNAs, to test the effects on cell behavior.19,29 
Similar types of assays have been performed to characterize the PLC pathway.90,91 Gene 
expression profiling can be done at the single-cell level: however, these assays are very 
expensive. Additionally, gene expression does not necessarily correlate with protein 
expression.92,93 For example, a study comparing mRNA and protein expression in primary 
monocytes from 30 subjects found increases in mRNA expression were usually accompanied by 
increases in corresponding protein expression.94 However, this correlation was very noisy, and 
only 5 of the 71 genes examined had a strong positive correlation across all subjects. In addition, 
enzyme expression does not necessarily correlate with enzyme activity, as a protein can be 
expressed without being active. This is partially due to the transient nature of enzyme activation 
states, which can change on a sub-second time-scale.95 In effect, a highly active enzyme that is 
weakly expressed has a much greater impact on cell behavior than a highly expressed enzyme 
that is completely inactive. Therefore, these indirect types of assays are not capable of measuring 
the activity of SK or PLC, and may in fact produce misleading results.  
 1.3.3 Microscopy 
 Microscopy is a technique that has been used extensively to measure single-cell enzyme 
activity.96 This can be achieved using an antibody specific to an active enzyme or the product of 
an enzyme reaction. For example, an antibody specific to PKB that has been phosphorylated at 
threonine 308 has been used to measure PKB activity in tumor cells.97 Another assay developed 
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for determining Bcr-Abl activity used an antibody that recognizes CT10 regulator of kinase like 
protein (CRKL), the primary substrate of Bcr-Abl, phosphorylated at the tyrosine 207 
residue.98,99 Antibodies can be tagged fluorescently or with an electron-dense substance, such as 
a heavy metal, and analyzed using optical or electron microscopy, respectively. One major 
advantage of microscopy is that it provides spatial resolution within an individual cell, enabling 
measurements of intracellular enzyme location in addition to enzyme activity. However, highly 
specific antibodies are notoriously difficult to make, especially for lipids, and are often affected 
by nonspecific binding.100 Phospho-specific antibodies also do not report on enzyme activity 
directly, because they are not traditionally used to measure comparative levels of products and 
substrates. Furthermore, even if specific antibodies for lipid substrates and products could be 
generated, any immuno-based assay would also require the cells to be fixed, a process that 
chemically lyses cells over a period of several seconds, which can trigger the cell stress response. 
This could potentially compromise measurements of SK and PLC activity, because both of these 
pathways can be activated in response to cell stress.101,102 Genetically encoded fluorescent fusion 
proteins can be utilized instead of antibodies to report enzyme expression and activity in single 
cells. For example, a fluorescence resonance energy transfer (FRET) biosensor was developed by 
fusing two fluorescent proteins to CRKL, enabling measurements of conformational changes 
upon phosphorylation of CRKL by Bcr-Abl.103 However, these types of reporters require 
modifications to cellular DNA, and are therefore not compatible for use with most primary 
cells.104 In addition, they commonly only result in a single fluorescent product, and cannot be 
used to characterize any downstream or off-target reactions. 
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1.3.4 Phosphoflow Cytometry 
 Flow cytometry is a high throughput technique capable of performing single-cell analysis 
at a rate of thousands of cells per second. In flow cytometry, cells are suspended in a stream of 
fluid, hydrodynamically focused, and detected using light scattering or fluorescence emission. A 
variation of flow cytometry, called phosphoflow cytometry, is utilized to measure the presence 
of phospho-specific antibodies in order to determine the phosphorylation state of intracellular 
proteins. Phosphoflow cytometry has been used to characterize kinase signaling in nonadherent 
cells, such as lymphocytes, for a vast range of biological applications.57,104,105 For instance, 
phosphoflow cytometry has been used to analyze phosphorylation at five residues on p53, a key 
tumor-suppressor kinase, in cells from AML patients.57,105,106 Other work demonstrated 
simultaneous measurements of three kinase signaling pathways with roles in apoptosis and T-cell 
activation in peripheral blood mononuclear cells (PBMCs) using phosphoflow cytometry.107 
Mass cytometry, a flow cytometry technique where inductively coupled plasma MS is used for 
detection, has been used to characterize changes in 34 parameters, including phosphorylation of 
kinases, in response to drug treatment in PBMCs.108 This study characterized hundreds of off-
target effects of dasatinib, a second-line inhibitor of Bcr-Abl, which could contribute to 
undesirable side effects of the drug. The advantages of mass cytometry compared to 
fluorescence-based flow cytometry is that it has the ability to simultaneously resolve dozens of 
metal probes. Fluorescence detection is limited by spectral overlap and is generally not capable 
of resolving more than 5-6 probes simultaneously. Although phosphoflow cytometry is a 
powerful single-cell technique due to its capacity for high throughput and resolution, it is limited 
by requiring the use of antibodies or genetically encoded reporters. Flow cytometry also requires 
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large numbers (104-106) of cells, making the method unsuitable for tissue specimens with small 
quantities of cells.  
1.3.5 Chemical Cytometry 
 Chemical cytometry is the analysis of the chemical composition of individual cells. 
Capillary electrophoresis (CE) and microchip-based CE (μCE) are two well-established 
techniques utilized for chemical cytometry. These techniques, which are described in more detail 
in Chapter 1.4, are capable of physically separating chemical constituents with extraordinary 
resolution, peak capacity, and LODs. Typically, CE and μCE systems coupled with laser-induced 
fluorescence (LIF) can reach subattomole detection limits. Dovichi et al. have even described a 
CE system capable of detecting yoctomoles of lipid analytes.109 These exquisite LODs, 
combined with high resolving power, make CE and μCE exceptionally promising techniques for 
single-cell analysis. In fact, chemical cytometry techniques have been utilized for the analysis of 
many biological molecules, including nucleic acids, proteins, lipids, peptides, and metabolites.110 
In one example, CE was used to characterize the expression of over 100 proteins in an individual 
embryo, demonstrating the high resolving power of this technique.111 Another μCE device was 
utilized to analyze acidic compounds in single mitochondria, organelles less than 5 μm in 
diameter.112 CE and μCE have been to measure the activity of enzymes, including phosphatases, 
peptidases, and kinases in single cells.113-115 Single-cell CE has even been used to characterize 
kinase activity, neurotransmitters, and glycosphingolipids in primary cells.116-118 One benefit of 
applying CE and μCE for quantification of enzyme activity is that the substrate, product, and all 
additional products formed from reactions with downstream or off-target enzymes can be 
physically separated and measured. These techniques therefore have the potential to measure the 
activity of dozens to hundreds of enzymes simultaneously from a single cell. Another advantage 
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of CE is that it can be used to analyze either adherent or nonadherent cells. In addition, CE does 
not require large numbers of cells, as flow cytometry does. In fact, single-cell CE has been 
performed with samples containing only a single isolated neuron.119 Although CE is a powerful 
technique for single-cell analysis, wider adoption has been hindered by low throughput. The 
causes of low throughput will be detailed in Chapter 1.4 and Chapter 2 will describe an 
automated CE system designed to increase the throughput of single-cell analysis. 
 
1.4 Capillary Electrophoresis 
1.4.1 Principles of Capillary Electrophoresis 
 CE is a process for separating molecules based on their mobility in a fluid-filled capillary 
under the influence of an applied electric field (Figure 1.3).120 To perform capillary zone 
electrophoresis (CZE), conducted in open tubular capillaries, analytes are injected at the inlet of 
a capillary filled with an electrolyte solution, termed electrophoretic buffer. Capillaries utilized 
for CZE are typically 20-200 μm in diameter, composed of fused silica, and protected with an 
outer polyimide coating. To initiate CZE, a high electric field is applied across the capillary, 
inducing migration of molecules through the capillary based on a combination of electroosmotic 
flow and electrophoretic mobility.121 Electroosmotic flow occurs due to the interactions between 
the ionized silanol groups (SiO-) on the inner capillary wall and cations in the electrophoretic 
buffer solution. This interaction forms an electric double layer composed of an innermost static 
layer of cations, called the Stern layer, and a diffuse outer layer with a high density of cations. 
This positive charge density decreases exponentially as the distance from the capillary wall 
increases. Upon the application of an electric field across the capillary, the cations concentrated 
in the diffuse outer layer of the electric double layer are attracted to the cathode and migrate 
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towards it. These ions are solvated, which causes them to drag liquid along with them, generating 
bulk fluid flow towards the cathode. The equation for electroosmotic mobility is defined by 
equation 1.1, where ε is the dielectric constant of the solvent, ζ is the zeta potential of the liquid-
solid interface, and η is the viscosity of the buffer. One advantage of electroosmotic driven flow 
is that it results in a relatively flat fluid velocity profile compared to pressure-driven flow, which 
generates a parabolic fluid velocity profile due to frictional forces between the mobile phase and 
the wall of the tube.122  
Equation 1.1 
 
μeo = electroosmotic mobility  
ε = dielectric constant 
 ζ = zeta potential  
η = viscosity 
 
 The electrophoretic mobility (μep), given in equation 1.2, depends on the size, shape, and 
charge of the analyte, as well as the viscosity of the solvent. The migration velocity of a 
spherical analyte, defined in equation 1.3, depends on the electroosmotic mobility of the buffer, 
the electrophoretic mobility of the analyte, the voltage applied across the capillary (V), and the 
total length of the capillary (L). The different electrophoretic mobilities between analytes allow 
them to be separated based on their size, shape, and charge. 
 Equation 1.2 
𝜇𝑒𝑝 =
𝑧𝑒
6𝜋𝜂𝑎
 

eo 

4
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μep = electrophoretic mobility 
z = charge of analyte 
e = charge of an electron 
η = viscosity 
a = hydrodynamic radius 
 
Equation 1.3 
𝑣 = (𝜇𝑒𝑜 + 𝜇𝑒𝑝)
𝑉
𝐿
 
ν = migration velocity 
μeo = electroosmotic mobility  
μep = electrophoretic mobility 
V = applied voltage 
L = length of the capillary 
 
 The number of theoretical plates (N), a measure of the efficiency of the separation, is 
directly proportional to the mobility of analyte and to the voltage applied across the capillary and 
indirectly proportional to the diffusion coefficient. For a given analyte, N can be calculated based 
on the migration time and the width of the peak using equation 1.4. Another test of separation 
performance is resolution (Rs), a measure of how well two analytes were separated. Equation 1.5 
shows that Rs is proportional to the square root of N and to the difference between the apparent 
mobilities (μep + μeo) of the two analytes divided by the average apparent mobilities of both 
analytes. Thus, decreasing the separation efficiency decreases resolution in a nonlinear fashion.  
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Equation 1.4 
𝑁 = 5.54 (
𝑡𝑚
√𝑤0.5
)
2
 
N = number of theoretical plates 
tm = migration time 
w0.5 = width of the peak at half height 
 
Equation 1.5 
𝑅𝑠 =
1
4
(
∆𝜇𝑎𝑝𝑝
𝜇𝑎𝑣𝑔
)𝑁1/2 
Rs = resolution 
μapp = apparent mobility  
μavg = average mobility  
N = number of theoretical plates  
 
One major advantage of CE is that the capillary provides highly efficient heat dissipation, 
minimizing Joule heating compared to techniques such as gel electrophoresis. Joule heating 
occurs when the heat generated due to the conduction of electrical current cannot be effectively 
dissipated, producing thermal gradients and inducing dispersion of analytes. The efficient heat 
dissipation of CE enables the application of high voltages across the capillary, which increases 
the velocity of the analytes and minimizes the impact of diffusion. Therefore, the most efficient 
CE separations occur at the maximum voltage that can be performed without causing Joule 
heating. Separation efficiency and resolution in CE are limited by a number of factors, including 
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diffusion, joule heating, interactions between the analytes and the capillary wall, and dispersion 
resulting from injections. Dispersion resulting from analyte interactions with the capillary wall is 
a frequent challenge with many biological analytes. This type of dispersion can be often be 
minimized using buffer additives, such as surfactants and organic solvents, that increase the 
solubility of analytes, preventing them from adhering to the capillary wall. Another strategy that 
can be used to prevent analyte adsorption is to use covalent or dynamic coatings to modify the 
surface of the capillary. One source of injection dispersion that is a common challenge in the 
analysis of biological samples is the use of high-ionic strength samples in a low-ionic strength 
separation buffer. Injecting samples with higher ionic strengths than the electrophoretic buffer 
results in dispersion due to differences in conductivity, and therefore electric field, across the 
sample and electrophoretic zones. These conductivity differences result in the analytes at the 
front of the sample zone migrating faster than the analytes in the middle of the sample zone, a 
process termed destacking. Under the right conditions, this process can be reversed, or the 
sample “stacked,” by injecting a sample with a lower ionic strength than the electrophoretic 
buffer. 
Due to the narrow diameter of the capillary, CE can be used to analyze very small 
volume samples (on the order of nL to pL). The narrow diameter and high separation efficiencies 
also work to preserve the concentration of the analytes, which gives CE very low limits of 
detection. In this dissertation, CE is used to separate lipids in their phosphorylated and 
nonphosphorylated states. This can be achieved because phosphorylated lipids are more 
negatively charged than their nonphosphorylated counterparts. This gives the lipid analytes 
different electrophoretic mobilities, enabling them to be separated in the capillary with high Rs. 
 22 
Other metabolic processes, such as hydrolysis, also cause changes in electrophoretic mobility 
that enable separation of multiple species of lipids.  
1.4.2 Single-Cell Capillary Electrophoresis 
CE has been utilized for the analysis of a wide range of biological molecules in single-
cells, including proteins, peptides, lipids, neurotransmitters, and RNA. The first single-cell CE 
systems were used to analyze fluorescently-labeled proteins119 and electrochemically active 
compounds123 in giant neurons from pond snails. Subsequent work has expanded the use of 
single-cell CE and has included measurements of biological analytes in a variety of different cell 
types, including adherent, nonadherent, and even primary mammalian cells. However, a major 
limitation of single-cell CE has been low throughput. Typical throughputs for single-cell analysis 
by CE are typically on the order of 1 – 2 cells per h.113,124 Single-cell CE throughput is limited by 
a number of tedious and labor-intensive manual processes, including isolating single cells, 
aligning the capillary above the cell of interest, transferring the capillary between a physiologic 
buffer necessary for maintaining cell viability and an electrophoretic solution designed for 
optimal separation conditions, and washing the capillary between each cell.124 These lengthy 
processes limit the throughput of single-cell CE, making it challenging to produce sufficient 
numbers of data points for many biological studies, due to the heterogeneity of cells.125 Several 
strategies have been developed to increase the throughput of single-cell CE analysis.126-131 The 
Dovichi group designed a single-cell CE system that utilized 1 nL microfabricated cell traps and 
an array of 5 capillaries to perform simultaneous injection and separation of single formalin-
fixed cells.127 However, the capture efficiency of single cells was low and limited the array of 5 
capillaries to an average analysis of only 2 cells per run. In addition, the capillary alignment and 
buffer transfer steps had to be performed manually. The fastest single-cell CE systems have 
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utilized serial analysis, the sequential injection and separation of multiple individual cells. The 
Lillard group designed an electroosmotic flow-based interface that continuously injected cells 
suspended in an electrophoretic buffer into a capillary for subsequent CE analysis.130 This system 
achieved a rate of analysis of 0.25 cells/min: however, the effect of suspending cells in non-
physiologic conditions on cell viability was not characterized. The Allbritton group utilized 
microfabricated cell traps and automated buffer transfer to perform serial analysis at a rate of 1.8 
cells/min.131 Although this system was significantly faster than typical CE assays, it was not fully 
automated, sufficiently robust to analyze more than tens of cells, or demonstrated to be capable 
of analyzing biological analytes. 
1.4.3 Single-Cell Analysis with Microfluidic Capillary Electrophoresis 
 Microfluidic devices for chip-based single-cell CE have achieved significantly higher 
throughputs compared to CE systems. McClain et al. separated fluorescent dyes from single-cells 
at a rate of 7-12 cells/min using a microfluidic device that incorporated hydrodynamic cell 
transport, cell lysis, and automated injection and separation.132 The device was used to analyze a 
total of 139 cells. Phillips et al. improved upon this device to perform separations of fluorescent 
dyes in 600 individual cells at a rate of 30 cells/min.133 These devices were only used to separate 
fluorescent dyes, but even faster separations of biological analytes have been achieved by Xu et 
al., who performed single-cell analysis of glutathione and reactive oxygen species at a rate of 38 
cells/min.134 Other μCE devices have been utilized for the analysis of biologically relevant 
compounds in single cells. For instance, a microfluidic device was used to measure nitric oxide 
production in stimulated immune cells at a rate of 10 cells/min.135 Another μCE device was 
utilized to measure changes in peptidase activity in response to chemotherapeutic treatment in 
hundreds of leukemic cells at an average rate of 30 cells/h.136 These devices can perform single-
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cell analysis at faster rates than traditional CE due to the short lengths of μCE separation 
channels, which are usually several centimeters compared to tens of centimeters in conventional 
CE. In addition, the processes of cell transport, lysis, injection, separation, and detection, have all 
been automated in μCE devices.133  
However, there are a number of limitations to μCE. These devices are difficult to adapt to 
adherent cell analysis, since they depend on hydrodynamic flow to transport cells. It is also 
challenging to adapt these devices to store and transport cells in physiologic buffer but conduct 
separations in electrophoretic buffer. This is because mixing occurs at the intersections of the 
buffers, and ensuring complete transport of the analytes and cell components between channels 
limits the combinations of buffers and coatings that can be used. Because of this, many single-
cell μCE systems use electrophoretic buffers that are optimized for device function, rather than 
high resolution separations. This decreases the separation efficiency tremendously compared to 
those that can be achieved with single-cell CE. For example, CE separation of fluorescent 
peptides with electrophoretic buffer optimized for separation efficiency resolved twice as many 
peptides as a μCE separation of the same peptides using buffer optimized for device function.136 
Alternatively, other μCE devices have performed all operations using non-physiologic buffers 
due to their higher separation capacities.137,138 However, these devices require exposing cells to 
conditions that could perturb vital biological processes and affect their viability. In addition, 
these non-physiologic buffers are often not fully optimized electrophoretic buffers, such as those 
used in CE, which often lyse cells upon contact. Many μCE devices also incorporate both 
hydrodynamic and electroosmostic flow and fluctuations in either of these can alter the 
performance of the device. For instance, the amounts of certain analytes injected into a 
separation channel were found to vary dramatically depending on small changes in pressure-
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driven flow.139 In comparison, single-cell CE is highly robust and stable, and buffer exchange is 
facile, enabling high efficiency separations. Single-cell CE can be performed with either 
adherent or nonadherent cells, and is limited mainly by low throughput. Increasing the 
throughput of single-cell CE to be competitive with microfluidic devices would therefore create 
a relatively fast chemical cytometry technique without losing the major advantages of CE.  
 
1.5 Overview of the Dissertation 
 The following chapters of this dissertation will describe measurements of lipid enzyme 
activity in single leukemic and immune cells using an automated single-cell CE system. Chapter 
2, which has been published in Analytical Chemistry, will describe the development and 
characterization of the higher throughput single-cell CE system.140 Chapter 3 will discuss the 
analysis of single-cell SK activity in peripheral blood mononuclear cells (PBMCs) from patients 
with leukemia. This chapter has been accepted for publication in Analytical and Bioanalytical 
Chemistry.141 In Chapter 4, the analysis of lipid enzymes in the SK pathway in single NK cells 
will be discussed. This chapter is in preparation to be submitted as a manuscript in the near 
future. Chapter 5 will describe preliminary work on the development of a treatment to prevent 
lipid biofouling, enabling the coupling of immunofluorescence microscopy and automated 
single-cell CE for characterization of SK and PLC activity in primary immune cells. 
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1.6 Figures 
 
Figure 1.1: Schematic of the SK pathway. In the de novo synthesis pathway, ceramide is 
produced from sphinganines and then converted to sphingosine by CDase. Sphingosine is 
converted to sphingosine-1-phosphate (S1P) by SK or is converted by back to ceramide by 
ceramide synthases (CerS). S1P can be dephosphorylated by S1P phosphatase (S1PP). S1P can 
be further cleaved into ethanolamine phosphate (EP) and hexadecenal by S1P lyase (S1PL). 
Hexadecenal is further converted into hexadecenoic acid, which forms the building blocks of a 
number of glycerolipids, including phoshatidylcholine. 
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Figure 1.2: Schematic of the PLC pathway. (A) PLC irreversibly hydrolyzes PIP2 into IP3 and 
DAG. (B) PIP2 can be converted to a number of important second messengers by kinases (dark 
gray arrows) and phosphatases (light gray arrows). It can be directly acted on by 
phosphoinositide 3-kinase (PI3K), phosphoinositide 5-phosphatase (P5P), and PLC. 
Abbreviations: phosphatase and tensin homolog (PTEN), phosphoinositide 5-kinase (PI5K), 
phosphatidylinositol 3,4-bisphosphate (PI(3,4)P2), src homology 2-containing inositol 
phosphatase (SHIP), and phosphoinositide 3-kinase type II (PI3KII).  
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Figure 1.3: Schematic of a capillary electrophoresis system. A capillary is filled with 
electrophoretic buffer and a high voltage is applied across a capillary. The electrophoretic buffer 
flows towards the cathode due to electroosmotic flow. Analytes injected into the capillary are 
separated based on their electrophoretic mobilities and are detected using LIF. 
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CHAPTER 2: AUTOMATED CAPILLARY ELECTROPHORESIS SYSTEM FOR FAST 
SINGLE-CELL ANALYSIS 
 
 
 
2.1 Introduction 
2.1.1 Sphingosine Kinase Activity in Acute Myeloid Leukemia 
Upregulation of SK increases drug resistance in a number of cancers, including acute 
myeloid leukemia (AML), the deadliest form of adult leukemia.1−3 SK converts sphingosine to 
sphingosine-1-phosphate (S1P), a stimulator of cell growth, differentiation, migration, and 
survival.4 Inhibitors of SK activity have been found to decrease chemotherapeutic resistance, 
even in multidrug resistant leukemic cells lines, and are currently in preclinical and clinical 
trials.2,5 The cell-to-cell variability in SK pathway dependence has important implications for the 
success of SK inhibitors as cancer therapeutics. Within a population of cells, a subset of cells 
may possess low SK activity and, therefore, exhibit inherent resistance to SK inhibitors. Indeed, 
the activity of many oncogenic kinases has been shown to vary drastically not only between the 
cancerous cells of different AML patients, but also by as much as 100-fold between 
individual cells in the same tumor.6,7 Increasing evidence in other tumor systems suggests that 
the single-cell heterogeneity in regulation of oncogenic signaling-pathways is a general feature 
of most cancers.8−10 Therapeutic inhibitors of SK activity currently in active development may 
have limited benefit if SK activity is highly variable among cells within a tumor. Thus, strategies 
to measure SK activity in large numbers of single tumor cells would assist in the characterization 
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of cell to-cell heterogeneity of this key signaling pathway while providing avenues to formulate 
individualized drug therapy for AML patients. 
2.1.2 Techniques for Measuring Sphingosine Kinase Activity 
Traditional measurements of SK activity involve extraction of sphingosine and S1P from 
cell lysates comprised of millions of cells, labeling the molecules fluorescently or 
radiometrically, and quantifying the amount of sphingosine and S1P using high performance 
liquid chromatography (HPLC),11,12 thin-layer chromatography (TLC),13 or fluorescence 
spectroscopy.14 The detection limits of these technologies range from 0.3 pmol for HPLC-MS to 
10 nmol for TLC. However, the predicted amounts of sphingosine and S1P within a single cell 
are (5−200) amol, below that of these analytical technologies. Capillary electrophoresis (CE), a 
separation technique that utilizes laser induced fluorescence to achieve low limits of detection, 
has been used to perform single-cell measurements of lipids, including phosphatidylinositol 
phosphates and glycosphingolipids.15,16 SK activity has been detected in as few as 10 cells using 
a fluorescent substrate, but single-cell measurements have not been achieved.17 
2.1.3 Increasing the Throughput of Single-Cell Capillary Electrophoresis 
Although traditional CE and chip-based CE (μCE) are powerful techniques for single-cell 
analysis, a major impediment to wider implementation of single-cell CE has been low throughput 
for biologically relevant analytes. Several strategies have been developed to address this 
problem, with the fastest single-cell CE platforms separating fluorescent dyes and biological 
analytes at rates of 1.8 cells/min18 and 0.25 cells/min,19 respectively.20−22 These systems 
performed serial analysis by sequentially injecting individual cells and then separating the 
cellular contents so that the analyte bands of sequential cells did not overlap at the detection 
window. These methods assessed a limited number of cells (≤ 30 cells) but incorporated 
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important features such as facile switching between cell and electrophoretic buffers. Higher 
throughputs have been achieved using microfluidic-based electrophoresis, the fastest of which 
separated glutathione and reactive oxygen species at a throughput of 38 cells/min for a total of 76 
cells.23 Microfluidic devices have also separated fluorescent dyes in as many as 600 total cells.24 
However, to date, μCE has been used for limited biological applications due to the difficulty in 
analyzing adherent cells and adapting devices for electrophoretic separations of biological 
analytes. This is primarily due to the difficulty in exchanging the cellular contents from a 
physiologic buffer into an appropriate electrophoretic buffer for separation.25 Although many 
single-cell CE and μCE systems expose cells to potentially stress-inducing phenomena such as 
electric fields, shear stress, and/or electrophoretic buffer, no systems have been characterized for 
their effect on cell homeostasis. This poses a potential challenge for this technology, as 
alterations in homeostasis have been shown to change basal cell physiology and can affect 
measurements of metabolic pathways and protein signaling cascades. Here, we present the 
design and optimization of a fully automated single-cell CE system capable of analyzing both 
adherent and nonadherent cells. The maximum throughput of the system for single-cell analysis 
was determined by separating the model dyes fluorescein and Oregon green. The separation 
performance of these analytes was compared to that performed with previously published single-
cell CE and microfluidic systems. Activation of protein kinase B (PKB) was measured in cells to 
determine whether the experimental steps prior to cell lysis altered stress-related biological 
pathways, potentially altering the outcome of kinase measurements. The single-cell CE system 
was then used to measure the phosphorylation of a fluorescent reporter for SK in the U937 
human myeloid leukemia cell line. The peak efficiencies, resolution, and rate of single-cell 
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separations of SF and S1PF were quantified. Over 200 cells were analyzed and the heterogeneity 
of SK activity between single cells was characterized. 
 
2.2 Experimental Design 
2.2.1 Reagents and Materials 
Sphingosine fluorescein (SF) and sphingosine-1-phosphate fluorescein (S1PF) labeled 
with the 5′ and 6′ isomers of fluorescein were purchased from Echelon Biosciences Inc. (Salt 
Lake City, UT) and were greater than 95% pure. Sodium dodecyl sulfate, boric acid, 1-propanol, 
sodium chloride, potassium chloride, magnesium chloride, piperazine-1-ethanesulfonic acid 
(HEPES), glucose, trypan blue, and poly-D-lysine were purchased from Sigma-Aldrich Inc. 
(St.Louis, MO). Fluorescein diacetate and Oregon green 488 carboxylic acid diacetate 6-isomer 
(Oregon green diacetate) were acquired from Molecular Probes (Eugene, OR, USA). Calcium 
chloride, sodium phosphate, potassium phosphate, tris-(hydroxymethyl)aminomethane (Tris), 
and pre-cleaned glass slides (50 mm x 45 mm x 1.5 mm) were procured from Fisher Scientific 
(Pittsburgh, PA). Dublecco’s Modified Eagle’s Medium (DMEM) and Roswell Park Memorial 
Institute Media (RPMI) were purchased from Cellgro (Manassas, VA), fetal bovine serum (FBS) 
from Atlanta Biologicals (Lawrenceville, GA), and penicillin/streptomycin from Gibco (Grand 
Island, NY). Paraformaldehyde and Triton X-100 were aquired from Thermo Scientific 
(Waltham, MA). EPON resin 1002F (phenol, 4,4’-(1-methylethylidene) bis-, polymer with 2,2’-
[(1-methylethylidene) bis (4,1-phenyleneoxymethylene)]bis-[oxirane]) was purchased from 
Miller-Stephenson (Sylmar, CA, USA). SU-8 developer (1-methoxy-2-propyl acetate) was 
procured from MicroChem (Newton, MA, USA). 
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2.2.2 Channel System Fabrication 
 Channels to contain the electrophoretic and physiologic buffers were fabricated from 
poly(dimethylsiloxane) (PDMS) (Sylgard 184). The length, width and depth of the 
electrophoretic buffer channel were 3 cm, 0.5 cm, and 1.5 mm, respectively. The channel 
containing physiologic buffer (135 mM NaCl, 5 mM KCl, 1 mM MgCl2 , 1 mM CaCl2 , 10 mM 
HEPES, 10 mM glucose, pH 7.4) was 3.5 cm in length. The width of the narrowest region was 
0.3 cm and the circular reservoirs at both ends of the channel were 1 cm in diameter. The 
electrophoretic and physiologic buffer channels were connected by an air-filled perpendicular 
channel 0.5 cm long and 1 mm wide. The PDMS channel system was bonded to a 1002F-coated 
coverslip and an array of cell traps fabricated into the 1002F was placed within the physiologic 
channel.26 Each trap in the 10 x 10 array was 30 μm in diameter and 20 μm in depth, and the 
distance between the centers of adjacent traps was 100 μm. The cell traps were fabricated as 
described previously.21 The cell trap array was placed in the center of the physiologic buffer 
channel, in line with the air-filled channel. 
2.2.3 Automation 
An inverted microscope (Ti-E, Nikon (Melville, NY)) was fitted with a computer-
controlled motorized stage (Ti-SER, Nikon). The channel system containing trapped cells was 
mounted on a temperature controlled stage insert, which was maintained at 37 °C. The address of 
each cell trap in the 10 x 10 array was calculated based on the manually determined positions of 
the four corner wells using customized software written in Python (Wolfeboro Falls, NH). The 
Python software also interfaced with the software controlling stage movement (Micromanager 
software, Vale Lab, UCSF) and single-cell electrophoresis system (LabVIEW, National 
Instruments, Austin, TX). The coordinates of each cell trap containing a single cell were 
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manually identified, recorded, and used to readdress that cell. A customized program (TestPoint, 
Measurement Computing, Norton, MA) was used to measure analyte fluorescence at the 
capillary-detection window as well as the current across the capillary. 
2.2.4 Capillary Electrophoresis 
 CE separation of fluorescein and Oregon green dyes was conducted at a field strength of 
510 V/cm using a borate-SDS buffer (45 mM borate and 20 mM SDS at pH 9.4). Separations of 
SF and S1PF were performed at 450 V/cm using a phosphate-propanol buffer (27 mM sodium 
phosphate and 10% 1-propanol at pH 7.3). Fused-silica capillaries (Polymicro Technologies, 
Pheonix, AZ) with an inner and outer diameter of 30 and 360 μm, respectively, were used for the 
electrophoresis. The total length of the capillary was 35 cm and the length from the inlet to the 
detection window was 4 cm. The short effective length of the capillary was made possible by 
mounting a custom-built epifluorescence detection system on the microscope stage, as has been 
described previously.18 
2.2.5 Cell Culture 
PC12 rat pheochromocytoma cells were grown in Roswell Park Memorial Institute 
(RPMI) medium containing 15% FBS and 1% penicillin/streptomycin and were used for assay of 
phosphorylated PKB. Rat basophilic leukemia (RBL) cells were cultured in Dublecco’s Modified 
Eagle Medium (DMEM) with 10% FBS and 1% penicillin/streptomycin and were used for the 
fluorescein/Oregon Green experiments. Phosphorylation of sphingosine was measured in U937 
human acute myeloid leukemia cells grown in RPMI media with 10% FBS and 1% 
penicillin/streptomycin. All cells were maintained at 37 °C in a humidified 5% CO2 
environment. 
 
 48 
2.2.6 Cell Loading with Fluorescent Reagents 
 RBL cells were loaded in cell traps in the channel system as described previously18 and 
then incubated at 37 °C in 5% CO2 for 2−3 h. Prior to CE analysis, RBL cells were incubated in 
physiologic buffer containing 250 nM Oregon green diacetate and 50 nM fluorescein diacetate 
for 25 min. The cells were then washed 5X with physiologic buffer and analyzed by CE. 
Nonadherent U937 cells were incubated in physiologic buffer containing freshly diluted SF (5 
μM) for 8 min, centrifuged for 3 min at 800X g, washed 5X with physiologic buffer, and then 
loaded into the cell traps. 
2.2.7 Single-Cell Capillary Electrophoresis 
For automated serial single-cell analysis, a trapped cell was moved directly under the 
inlet of the capillary, which was positioned 50 μm above the plane of the cells. The physiologic 
buffer (1 mm/s flow velocity, 35 °C) and the electrophoretic buffer (2 mm/s flow velocity, 25 
°C) were held at ground potential throughout the experiment. Excess buffer from both channels 
was removed by placing a vacuum line at the channel outlet ends. To analyze the contents of a 
cell, the cell was placed under the capillary and lysed by a focused laser pulse, as described 
previously.27 The cell contents were electrokinetically injected into the capillary by applying −5 
kV to the capillary outlet for 1 s. The voltage across the capillary was then set to zero for 1 s and 
the capillary was transferred through the air gap to the electrophoretic buffer. During buffer 
exchange, the capillary remained stationary and the channel system mounted on the microscope 
stage was moved. For the fluorescein/Oregon green analysis, a separation voltage of −18 kV was 
applied to the capillary outlet for either 14 s, for maximum throughput serial separations, or 52 s 
for low throughput serial separations. The separation voltage was −16 kV for 25 s for the 
SF/S1PF separation. The voltage was then set to zero for 1 s to move the capillary back to the 
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physiologic buffer and position it at the address of the next single cell to be analyzed. This 
process was repeated under computer control until all single cells in the array were analyzed. 
2.2.8 Activation of Cells with Nerve Growth Factor  
Glass coverslips or cell traps were treated with 1 M NaOH for 1 h, washed, and treated 
with 100 ng/mL poly-D-lysine for 1−12 h. PC12 cells were seeded on the treated coverslips or 
cell traps, and then incubated in RPMI media with 10% FBS and 5% FCS (24 h) and 
subsequently serum starved in RPMI media with 0.1% FBS (36 h). Cells were then stimulated 
with 100 ng/mL nerve growth factor (NGF) (Millipore, Billerica, MA) for 15 min, as described 
previously.28 
2.2.9 Immunofluorescence Assay for Phosphorylated Protein Kinase B 
The primary antibody used for the immunofluorescence assay was a phospho-PKB (Ser 
473) rabbit mAb and the secondary antibody was a goat antirabbit IgG tagged with an Alexa 
Fluor 488 conjugate, both purchased from Cell Signaling Technology (Danvers, MA). Blocking 
buffer (phosphate buffered saline (PBS) with 1% BSA) was purchased from Thermo Scientific 
(Waltham, MA). PC12 cells were fixed with 4% paraformaldehyde for 25 min and permeabilized 
by incubation in 0.1% Triton in PBS for 20 min. The samples were then incubated in blocking 
buffer (30 min), primary antibody diluted 1:200 in blocking buffer (1 h), blocking buffer (1 h), 
and finally in secondary antibody diluted 1:1000 in blocking buffer (45 min). Between 
incubations, the samples were washed 2x with PBS. Quantitative single-cell analysis of phospho-
PKB (the average fluorescence intensity of a cell) was performed using fluorescence imaging, as 
previously described.17 
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2.3 Results and Discussion  
2.3.1 Design of a Capillary Electrophoresis System for Single-Cell Analysis 
To increase the throughput of single-cell CE while maintaining cell health, an automated 
CE system was designed and optimized (Figure 2.1A). An array of 100 microfabricated cell-
sized wells was used to trap adherent or nonadherent cells at known addressable positions 
(Figure 2.1B). The cell trap array was positioned in an open PDMS channel where cells were 
continually exposed to fresh physiologic buffer (Figure 2.1C). Electrophoretic buffer was 
contained in a channel parallel to the physiologic buffer channel to prevent cell exposure to the 
cytotoxic electrophoretic buffer. These two channels were connected by a perpendicular channel 
filled with air that prevented mixing of the two buffer systems. The air was stably contained 
within the connecting channel because the surface tensions of the buffers were greater than the 
critical surface tension of the hydrophobic PDMS channel, which prevented wetting of the air 
channel. During analysis, cells were positioned under the capillary inlet, lysed, and 
electrokinetically injected into the capillary. The capillary then traversed the air channel to the 
electrophoretic buffer and separation of cellular contents was initiated by application of a voltage 
across the capillary. The capillary remained in the electrophoretic buffer during electrophoresis, 
after which time, the capillary returned to the physiologic buffer channel to the address of 
another cell to be analyzed. The process was then repeated. Capillary movement and alignment 
over a new cell required less than 1 s. 
2.3.2 Characterization of Separation Performance in the Absence of Cells 
This system was designed for the repeated injection of cellular contents, which required 
multiple plugs of cellular contents to coexist within the capillary, all undergoing separation 
simultaneously. However, physiologic buffers possess high salt concentrations, in contrast to 
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optimized electrophoretic buffers, which often feature low salt concentrations to minimize 
capillary current. Low ionic strength buffers enable efficient separations at maximal field 
strengths, but the differences in ionic strengths between the electrophoretic buffer and the 
physiologic buffer were expected to lead to destacking of the analyte plug, causing significant 
peak broadening. To determine how the presence of multiple high salt plugs within the capillary 
impacted separation performance, an equimolar mixture of fluorescein and Oregon green in 
physiologic buffer was repeatedly injected into the capillary and separated. To fully mimic the 
events during cell analysis, the dyes were placed in the physiologic buffer channel. A buffer 
plug (1.6 nL) was loaded into the capillary, which was then moved into the electrophoretic buffer 
channel, and electrophoresis was initiated. After 10 s, the capillary was moved back into the 
physiologic buffer channel, a second plug injected, and the process repeated. Serial analyte 
injections were performed in this manner at a rate of 5.5 injections/min. Under these conditions, 
23 high-salt analyte plugs were present simultaneously in the capillary (0.7 plugs/cm capillary). 
For each plug loaded, two peaks were visualized on the electropherogram, one of which co-
migrated with fluorescein and the other with Oregon green (Figure 2.2, Table 2.1). The 
resolution was 3 ± 0.5 and the peak efficiencies were 7000 ± 1000 (4-cm effective capillary 
length) for the fluorescein peak and 2300 ± 900 for the Oregon green peak. For comparison, a 
single plug of the fluorescein/Oregon green mixture loaded into the capillary and electrophoresed 
exhibited peak efficiencies for fluorescein and Oregon green of 8300 ± 600 and 4000 ± 400, 
respectively with a resolution of 8.2 ± 0.4. As expected, deterioration in separation performance 
occurred due to the multiple high ionic-strength plugs within the low-ionic strength 
electrophoretic buffer. The separation performance of Oregon green was more markedly 
decreased than that of fluorescein, likely due to the higher charge of Oregon green, which made 
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it more susceptible to destacking.29 However, robust separation of the two dyes remained 
possible with good peak area (0.78 ± 0.02 for fluorescein and 1.09 ± 0.03 for Oregon green) and 
migration time (29.2 ± 0.3 s for fluorescein and 34.1 ± 0.2 s for Oregon green) reproducibility. 
These results suggested that separation of fluorescein and Oregon green from single cells would 
be possible with this system. Importantly, this simple test strategy could be utilized to predict 
which buffer/analyte combinations could be employed successfully with this single-cell analysis 
platform. 
2.3.3 Separation of Fluorescein and Oregon Green from Single Cells 
To determine whether the model dyes could be separated from single cells, cells were 
preloaded with the dyes and single-cell analysis was performed in an automated fashion at 1.2 
cells/min and with 5 sample plugs in the capillary (0.1 plugs/cm). The electropherograms 
obtained from the single cells exhibited two fluorescent peaks with migration times 
corresponding to that of fluorescein and Oregon green (Figure 2.3, Table 2.2). The migration 
times of the fluorescein and Oregon green peaks were not stable for the first 5 cell-lysate plugs 
loaded into the capillary with times of 28.5 ± 2 s and 34 ± 5 s (n = 5), respectively (Figure 2.4, 
Supporting Information). This was most likely due to the changing local field strengths within 
the capillary as more high salt buffer plugs were introduced. After the first 5 plugs, the 
reproducibility in migration time improved: 26.3 ± 0.3 and 30.9 ± 0.5 s for fluorescein and 
Oregon green (n = 7), respectively. When the capillary was preloaded with 10 plugs of 
physiologic buffer prior to single-cell analysis, the migration times were 26.3 ± 0.3 and 31.4 ± 
0.6 s, respectively (Figure 2.4). The peak efficiencies of fluorescein and Oregon green peaks 
were 2000 ± 800 and 3000 ± 1000, respectively, with a resolution of 1.8 ± 0.5. Thus, the 
presence of the cellular constituents decreased separation performance relative to that of the dyes 
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dissolved in the physiologic buffer solution. This was most likely due to binding of the dyes to 
cellular components and adsorption of cellular debris onto the capillary walls.30  
To determine whether a higher single-cell analysis rate could be attained without 
degrading separation performance, cells were injected and separated at a rate of 3.5 cells/min, 
which corresponded to 15 sample plugs present simultaneously within the capillary (0.4 
plugs/cm). For these experiments, the capillary was preloaded with 15 physiologic buffer plugs 
and then single-cell CE was initiated. The efficiency, migration times and resolution were similar 
to that attained at the lower rate of single-cell analysis (Table 2.3). Thus, the throughput of the 
automated system could be increased to 3.5 cells/min without compromising the system 
performance. The separation quality and cell throughput was compared to the separation 
performance of previously published serial-analysis capillary and microfluidic systems (Table 
2.3).18,31 Remarkably, this system brings the capillary-based approach close to the throughput of 
the microfluidic system with similar separation performance but with a much greater flexibility 
in the electrophoretic buffer utilized. 
2.3.4 Measurement of Phosphorylated Protein Kinase B in Cells Prior to Assay 
Accurate measurement of model dyes from cells is possible irrespective of the cell’s 
condition as long as the cell’s membrane is intact so that the dyes remain intracellular. However, 
accurate measurement of many cellular properties, for example, kinase activation, requires that 
the cell remain unperturbed until cellular reactions are terminated at the moment of lysis. Many 
enzymes, including SK, are activated in response to stresses placed on a cell, such as hypotonic-
buffer exposure, shear forces, and chemical insult.32 Thus, it was important to assess cell health 
following exposure to potential insults such as epoxy photoresist contact, adjacent cell lysis, 
electrophoretic buffer contamination, and other factors during the assay process. Phosphorylated 
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PKB was measured as a marker for cell stress since phosphorylation is altered in response to a 
diverse array of cellular stresses including oxidative, hyperosmotic, hypoosmotic,33 and 
nonphysiologic chemical exposure.34−36 The cellular stressors introduced by this system were 
assayed by measuring alterations in single-cell basal phospho-PKB during: (i) culture in the 
1002F cell traps, (ii) incubation in low concentrations of electrophoretic buffer, and (iii) a mock 
single-cell CE assay, where cells were exposed to the full conditions of the assay prior to lysis, 
including the effect of laser-based cell lysis on nontargeted, adjacent cells.  
1002F photoresist has previously been shown to be biocompatible in that cells can grow 
and divide when cultured on a 1002F surface.26 However, more subtle effects on cellular health, 
such as induction of cell stress responses, have not been examined. Cells were cultured on glass 
surfaces or in 1002F cell traps for 60 h and phospho-PKB was measured by 
immunofluorescence. Cellular fluorescence, or phospho-PKB levels, were indistinguishable on 
the two surfaces (Figure 2.5). As a positive control, cells on the two surfaces were stimulated 
using nerve growth factor (NGF), which is known to activate PKB. Phospho-PKB levels were 
identical in cells grown on the different surfaces (Figure 2.5). These data demonstrate that 
culturing cells in 1002F traps do not elevate cell stress relative to culture on a glass surface. 
Electrophoretic buffers generally possess nonphysiological chemicals, low ionic 
strengths, and non-neutral pH, all of which might alter cellular physiology and activate stress 
pathways. As the capillary is withdrawn from the electrophoretic buffer solution for transfer back 
to the physiologic buffer, a meniscus forms on the capillary end due to surface tension.37 
Therefore, small amounts of electrophoretic buffer were expected to be transported by the 
capillary into the physiologic buffer as the capillary was moved back and forth between the two 
buffer channels. To quantify the amount of liquid that the capillary transferred, the 
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electrophoretic buffer channel was filled with a trypan blue solution and the physiologic buffer 
channel was filled with water. The capillary was repeatedly moved between these two solutions 
and the amount of trypan blue in the water-filled channel was measured using its absorbance at 
607 nm. Each movement of the capillary between the channels transferred 8 ± 1 nL of 
electrophoretic buffer into the physiologic buffer channel (Figure 2.6). For a physiologic buffer 
volume of 400 μL, 100 capillary movements would yield a 0.2% (v/v) contamination of 
electrophoretic buffer in the physiologic buffer. 
To characterize the impact of low-level electrophoretic buffer contamination in the 
physiologic buffer, phospho-PKB was measured in cells incubated in physiologic buffer 
containing 0−1% electrophoretic buffer. Three common electrophoretic buffers with a variety of 
chemical constituents: Tris (100 mM Tris at pH 7.4), borate-SDS, and phosphate-propanol were 
assessed. Borate-SDS and phosphate-propanol buffer were additionally chosen because they 
were used for the fluorescein/Oregon green and SF/S1PF separations, respectively. The number 
of cells exhibiting phospho-PKB levels greater than 3X the standard deviation of the average 
phospho-PKB level in untreated cells was calculated. Increasing electrophoretic buffer 
contamination led to greater numbers of cells with increased phospho-PKB levels for all three 
buffers (Figure 2.7A). The borate-SDS buffer system yielded the highest levels of phospho-PKB 
at each of the concentrations tested, increasing phospho-PKB levels relative to untreated cells 
with as little as 0.1% contaminating electrophoretic buffer. The phosphate-propanol buffer 
caused the smallest increase in phospho-PKB, requiring at least 1% buffer contamination to 
increase phospho-PKB amounts in the cells. These experiments suggest that exposing cells to 
even very low concentrations of electrophoretic buffer can alter signaling pathways. Although 
the separation performance of single-cell CE and μCE systems can be improved by injecting 
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cells in electrophoretic buffer to prevent destacking, as several systems have previously done,19,38 
measurements made in these systems may not accurately reflect basal cellular physiology. 
Laser-based cell lysis acts by creating an expanding and collapsing cavitation bubble that 
mechanically disrupts cells.27 While bubble size is limited, fluid movement around the bubble is 
initiated and could impact nearby cells. To assess the effects of laser-based lysis of targeted cells 
on the adjacent nontargeted cells in cell traps, as well as the other possible stressors during the 
assay (electric fields during electrokinetic injection, shear stress from buffer flow, and 
electrophoretic buffer contamination) phospho-PKB was measured in cells during a mock cell-
assay protocol. The capillary was positioned 100 μm from a trapped cell (over an empty well) 
and a focused laser pulse was delivered below the capillary, as would be performed for actual 
cell lysis. A voltage was applied to the capillary to load a buffer plug and the capillary was 
moved to the electrophoretic buffer channel. This process was repeated for each cell on the array 
that was adjacent to an empty cell trap. The mock assay had no detectable effect on phospho-
PKB activity, compared to control cells without exposure to a nearby laser pulse or capillary 
(Figure 2.7B, C, and F). To test for phospho-PKB inhibition, a group of positive control cells 
were stimulated with NGF and the cells divided into a control and mock-assay group. These 
NGF-stimulated cells exhibited increased phosphorylation of PKB, with the control and test 
groups demonstrating similar numbers of cells with elevated phospho-PKB (Figure 2.7D− F). 
These results suggested that the single-cell assay did not increase cell stress levels nor did the 
assay procedures inhibit appropriate cellular responses to stimuli prior to cell lysis. 
2.3.5 Measurement of Sphingosine-1-Phosphate Fluorescein Formation in Single U937 
Cells 
 
Once a fast cell assay-system was designed and characterized, formation of S1PF could 
be measured in large numbers of cultured U937 cells, a myeloid leukemia cell line. Cells were 
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incubated with SF, washed, and then loaded into the cell traps. Single cells were then serially 
assayed for fluorescent SF metabolites. The separation voltage was applied for 25 s after the 
contents of a single cell were loaded into the capillary, yielding a throughput of 2.1 cells/min for 
a total of > 200 cells. The electropherograms of each cell possessed 1, 2, or 3 peaks (Figure 
2.8A). A peak with an average migration time of 30 ± 1 s co-migrated with SF and a peak that 
migrated at 41 ± 2 s co-migrated with S1PF. A third peak, present in 7% of cells, migrated at 
35.0 ± 0.9 s, between the SF and S1PF peaks. The resolution between the SF and S1PF peaks 
was 3 ± 1.5 and the efficiency of the SF and S1PF peaks was 1300 ± 800 and 2000 ± 1000, 
respectively. The molar amounts of SF, S1PF, and the unknown compound in cells, calculated by 
comparing peak areas measured in cells to those measured using a standard solution with known 
concentrations of SF and S1PF, varied from approximately 0.1− 10 amol with an average of (0.5 
± 2) amol and (6 ± 8) amol for SF and S1PF, respectively (Figure 2.8). The percent of 
phosphorylated reporter (S1PFmoles / (SFmoles + Unknownmoles + S1PFmoles)) in a cell ranged from 
0 to 100% with an average of 90 ± 30% and did not depend on the total amount of reporter 
loaded into the cells (R2 = 0.003) or the time of the measurement (R2 = 0.06) (Figure 2.8 and 
Figure 2.9). Thus, most cells demonstrated a large capacity to convert SF to S1PF without 
saturating SK. A comparison of the percent of SF phosphorylated in single cells revealed that 
population average did not capture the distinct subpopulations of cells present (Figure 2.8C). The 
majority of cells (83%) had greater than 80% S1PF. Eleven percent of the cells possessed 1−80% 
phosphorylation, and another 6% demonstrated less than 1% phosphorylation. These categories 
were also independent of the amount of SF loaded into the cell and the time of the measurement. 
Thus, significant heterogeneity existed among the cells in terms of S1PF formation as well as the 
amount of total reporter loaded. The high levels of S1PF formation in the majority of these 
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cultured cells is consistent with prior work demonstrating that SK inhibitors can decrease AML 
cell survival.2 However, the existence of cell subpopulations with low to moderate SK activity 
indicate that SK inhibitors might not be equally effective on all cells, suggesting that alternative 
therapies may be necessary to target AML cell populations not dependent on increased SK 
activity. 
2.4 Conclusions  
A robust, fully automated system for serial single-cell CE was developed and 
characterized. The system presented here performs faster analyses of fluorescent dyes and 
biologically relevant analytes than any prior capillary-based designs. The flexibility in 
electrophoretic buffer selection opens the door for the analysis of a wide range of biological 
compounds in single cells without stimulating a cell stress-response. The system was sufficiently 
robust to analyze >200 cells and to identify subpopulations of SK activity in the cultured U937 
cells. This examination of heterogeneity in SK upregulation at the single-cell level adds to 
existing evidence that indicates SK inhibition could be an effective method for treating leukemia, 
although it also suggests that for total annihilation of leukemia cells, combination therapies will 
be important. Our long-term goal is to enable targeted drug therapy for AML patients with 
upregulated SK activity. Additionally, this single-cell CE system will enable higher throughput 
measurements of a wide range of biological compounds in future studies. 
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2.5 Figures and Tables 
 
Figure 2.1: System for serial assay of single cells. (A) Schematic of the channel system with 9 of 
100 cell traps shown in the inset. (B) Bright-field image of 9 cell traps of which 8 are loaded 
with cells. The lower left trap is empty. (C) Image of the channel system with both channels 
filled with a trypan blue solution. The capillary is positioned over the cell traps. (D) 
Electropherogram of serial single-cell analysis of 59 cells preloaded with fluorescein (*) and 
Oregon green (**). (Inset) Expanded region of the electropherogram. 
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Figure 2.2: Electropherogram of serial analysis of 10 nM fluorescein (*) and Oregon green (**) 
in a physiological buffer solution. The inset shows an expanded region of the electropherogram. 
The throughput of analysis was 5.5 separations/min. 
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Figure 2.3. Electropherogram of serial single-cell analysis of 10 cells pre-loaded with fluorescein 
(*) and Oregon green (**). The inset shows an expanded region of the electropherogram. The 
throughput of analysis was 1.2 cells/min. 
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Figure 2.4: Migration times (tm) of Oregon green (OG) and fluorescein (Fl) peaks during serial 
analysis of cells at a throughput of 1.2 cell/min. (A) Cells were injected and separated in a 
capillary initially filled with electrophoretic buffer. (B) Cells were injected and separated in a 
capillary that was pre-loaded with 10 plugs of physiologic buffer distributed evenly across the 
length of the capillary. 
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Figure 2.5: Phospho-PKB measured using an immunofluorescence assay. Normalized 
fluorescence intensity (average fluorescence intensity per cell normalized to the fluorescence 
intensity of untreated control cells) for nerve growth factor (NGF) stimulated cells seeded on a 
glass slide [Glass (+)], untreated cells on glass [Glass (-)], untreated cells incubated in 1002F cell 
traps [Cell traps (-)], and NGF stimulated cells [Cell traps (+)] incubated in cell traps.  
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Figure 2.6: Volume transferred between electrophoretic and physiological buffer channels due to 
capillary movement between the buffers (Buffer Exchanges). 
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Figure 2.7: Measurement of phospho-PKB in cells. (A) Percent of cells with elevated phospho-
PKB when varying concentrations (0−1%) of electrophoretic buffers were intermixed with 
physiologic buffer. Each bar is the average of 3 experiments consisting of ≥ 50 cells each. The 
error bars represent the standard deviation. “Borate” represents the borate-SDS buffer while 
“Phosphate” describes the phosphate-propanol buffer. (B) Bright-field and fluorescence images 
of cells incubated in 1002F cell traps. (C) Bright-field and fluorescence images of cells incubated 
at a distance of 100 μm from regions in which a focused laser pulse was fired and a buffer plug 
was electrokinetically loaded into the capillary. (D) Cells treated as in panel B but with prior 
exposure to NGF. (E) Cells treated as in panel C but with prior exposure to NGF. (F) Percent of 
cells with elevated phospho-PKB corresponding to the experimental conditions shown in panels 
B−E. Each bar is the average of 3 experiments consisting of 100 cells. The error bars represent 
the standard deviation. 
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Figure 2.8: Measurement of SK activity in single U937 cells. (A) Typical electropherogram of 
the serial separation of SF (*), S1PF (**), and an unknown (?) in 35 single cells. (B) Percent of 
phosphorylated reporter (S1PFmoles/(SFmoles + S1PFmoles + Unknownmoles)) plotted against the total 
moles of reporter loaded into the cell (SFmoles + S1PFmoles + Unknownmoles) for each cell (n = 
219). (C) Histogram of the percent of cells with different levels of phosphorylated reporter 
(S1PFmoles/(SFmoles + S1PFmoles + Unknownmoles)).  
 67 
30 40 50 60 70 80 90 100
0.1
1
10
SF
S1PF
Unknown
L
o
g
(A
tt
o
m
o
le
s
)
Time of Analysis
 
Figure 2.9: The total molar amount of SF, S1PF, and the unknown compound in U937 cells. 
Time zero is at the start of cell incubation with the SF reporter. 
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Table 2.1: Comparison of the separation of fluorescein (Fl) and Oregon green (OG) in the 
absence of cells using standard CE or serial analysis at a throughput of 5.5 injections/min.  
    tm (s) 
Peak Efficiency (N 
x 103)   
Separation  
Method 
Max # Plugs 
in Capillary Fl OG Fl OG R 
Single-sample 
(Standard CE) 
1 29.9±0.5 42.8±0.7 8.3±0.6 4±0.4 8.2±0.4 
Serial Analysis 23 29.2±0.3 34.1±0.2 7±1 2.3±0.9 3±0.5 
tm is the average migration time  
R is the resolution between fluorescein and Oregon green peaks 
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Table 2.2: Comparison of separation performance during serial single-cell analysis at a 
throughput of 1.2 cells/min. 
    tm (s) 
Peak Efficiency 
(N x 103)   
Cells Analyzed 
Max # Plugs in 
Capillary Fl OG Fl OG R 
Cells 1-5 5 28.5±2 34±5 8±4 4±2 4±2 
Cells 6-12 5 26.3±0.3 30.9±0.5 6±5 2±1 1.9±0.8 
All cells (pre-
loaded)* 
5 26.3±0.3 31.6±0.6 2±0.8 3±1 1.8±0.5 
tm is the average migration time  
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Table 2.3: Comparison of the separation of fluorescein (Fl) and Oregon green (OG) from single 
cells using capillary or microfluidic systems. 
  
Peak Efficiency  
      (N x 104) 
Chemical 
Cytometry System Fl OG Resolution 
tm (% 
RSD) 
Throughput 
 (cells/min) 
Automated 
Capillary (current 
system) 
 
0.2 ± 0.1 0.3 ± 0.2 2.3 ± 0.6 3.4 3.5 
Jiang et al. 
Capillary18 
 
0.3 ± 0.1 0.2 ± 0.09 2.7 ± 0.5 3.5 1.8 
Microfluidic 
Device31 
* 0.38 * 4.8 7 - 12 
tm is the average migration time  
*Information not provided 
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CHAPTER 3: SINGLE-CELL SPHINGOSINE KINASE ACTIVITY MEASUREMENTS 
IN PRIMARY LEUKEMIA 
 
 
 
3.1 Introduction 
3.1.1 Sphingosine Kinase in Leukemia 
Sphingosine kinase (SK) is an important regulator of cell fate that converts sphingosine, a 
lipid signaling molecule, which induces apoptosis, to sphingosine-1-phosphate (S1P), which 
promotes cell survival, proliferation, and migration.1-3 Because of its central role in regulating 
cell survival, S1P overexpression has been implicated in a number of cancers, including 
leukemia, prostate, breast, colon, pancreatic, and lung cancers.4,5 Leukemia is one of the most 
prevalent cancers, and is the deadliest cancer for people below the age of 20 in the United 
States.6 Targeting the SK pathway has been effective at inducing apoptosis in multiple types of 
leukemic cells.7 Inhibition of SK in cultured and primary leukemic cells also increases their 
sensitivity to chemotherapy, even in cells that have become multi-drug resistant.8,9 Notably, SK 
inhibitors induce apoptosis in primary acute myeloid leukemia (AML) cells at a much higher rate 
than in healthy cells.8 SK is also overexpressed in chemotherapeutic-resistant CML cell lines10 
and is thought to regulate drug resistance by increasing the stability of Bcr-Abl, the oncogenic 
fusion protein that is the proximate cause of CML.11 Drugs that target SK activity in cancer are 
currently in multiple clinical trials and are especially promising for treating drug-resistant 
leukemia.12  
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3.1.2 Methods for Measuring Intratumor Heterogeneity of Sphingosine Kinase Activity 
 One challenge facing the development of novel cancer therapeutics is that cells from the 
same tumor can have extraordinary phenotypic and functional heterogeneity.13,14 Intratumor 
heterogeneity has been demonstrated to have profound implications for disease evolution, patient 
prognosis, and the development of drug resistance.15 Despite the important implications of tumor 
heterogeneity in treating leukemia,16-18 very little is known about the variability of SK activity at 
the single-cell level in primary leukemia. Conducting single-cell lipid kinase measurements in 
primary cells is difficult due to the challenges in generating antibodies specific for endogenous 
lipids, limited availability of patient samples, and a lack of robust technologies with single-cell 
limits of detection. Microscopy and flow cytometry are powerful methods that have been 
commonly used for single-cell analysis. In particular, phospho-specific flow cytometry, which 
utilizes antibodies against phosphorylated proteins, has enabled characterization of the activity of 
many kinases in primary samples.19,20 However, without commercially available antibodies 
specific to sphingosine and S1P, SK activity cannot be directly measured using these techniques. 
In addition, flow cytometry requires large numbers (104-106) of cells, making the method 
unsuitable for patient specimens with small numbers of cells.21 Microscopy has been utilized to 
measure single-cell enzyme activity with fluorescent protein probes, but these probes must be 
genetically encoded, which limits their application in primary cells.22 Separation techniques 
capable of physically distinguishing sphingosine and S1P, such as high performance liquid 
chromatography with mass spectrometry detection, are commonly used to measure sphingolipids 
in ensemble samples of hundreds of thousands of cells, but the limits of detection are far too high 
to detect these analytes in single cells.23  
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Capillary electrophoresis (CE) with laser-induced fluorescence detection is a promising 
technology for kinase activity measurements in single, primary cells. Typical CE limits of 
detection for fluorescent species are in the sub-attomole level, sufficiently low to quantify 
molecules from single cells.24,25 Single-cell CE has been utilized to measure lipid metabolism 
and enzyme activity in a number of cell types.26-28 However, the majority of single-cell CE 
research has used immortalized cell lines for enzyme activity measurements. Although these cell 
lines are a convenient and often useful model system, there is increasing evidence that they may 
not resemble primary cells in terms of function, behavior, and physiological signaling.29 Indeed, 
among the few studies that have performed single-cell CE analysis of enzymatic activity in 
primary cells, including rat brain neurons,30 human airway epithelial cells,31 and human 
pancreatic tumor cells,32 at least two found differences in activity between primary cells and 
cultured cells.31,32 There is a clear need for studies applying CE measurements to primary cells to 
increase the availability of this technology for clinically relevant measurements on cells. 
3.1.3 Measuring Single-Cell Sphingosine Kinase Activity in Primary Leukemia 
This paper will describe the use of automated single-cell CE to characterize SK activity 
in tissue-cultured cells of leukemic origin, PBMCs from leukemia patients, and purified 
leukemic blasts. Assay performance was optimized in the leukemia-derived K562 cell line. The 
metabolism of the fluorescent sphingosine was then quantified in these cells. Ensemble 
measurements of frozen and fresh PBMCs from patients with leukemia were compared to 
determine whether freezing cells altered SK activity in the primary cells. Phosphorylation of the 
SF reporter was then measured in single PBMCs, which were composed of a mixed population 
of leukemic blasts and normal leukocytes. Reporter uptake, phosphorylation, and the number of 
fluorescent metabolites in each cell were measured in the PBMCs from CML, AML, and B-ALL 
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patients. SK activity was also measured in isolated leukemic blasts from a fourth patient with 
AML. In total, over 100 patient cells were analyzed and SK heterogeneity within each patient 
was characterized. 
 
3.2 Experimental Design 
3.2.1 Reagents and Materials 
Sphingosine 5/6-fluorescein (SF) and sphingosine-1-phosphate 5/6-fluorescein (S1PF) 
were purchased from Echelon Biosciences Inc. (Salt Lake City, UT). Sodium chloride, potassium 
chloride, magnesium chloride, calcium chloride, piperazine-1-ethanesulfonic acid (HEPES), and 
glucose were acquired from Sigma-Aldrich Inc. (St. Louis, MO). Monosodium phosphate, 1-
propanol, methanol, isopropanol, and pre-cleaned glass slides (50 mm x 45 mm x 1.5 mm) were 
procured from Fisher Scientific (Pittsburgh, PA). Ethanol was acquired from Decon Labs (King 
of Prussia, PA). Roswell Park Memorial Institute Media (RPMI) was purchased from Cellgro 
(Manassas, VA) and Adoptive Immunotherapy Media (AIM-V®) was acquired from Gibco 
(Grand Island, NY). Fetal bovine serum (FBS) was purchased from Atlanta Biologicals 
(Lawrenceville, GA), human AB serum (HS) from Gemini BioProducts, and 
penicillin/streptomycin from Gibco (Grand Island, NY). EPON resin 1002F (phenol, 4,4’-(1-
methylethylidene) bis-, polymer with 2,2’-[(1-methylethylidene) bis (4,1-
phenyleneoxymethylene)]bis-[oxirane]) was procured from Miller-Stephenson (Sylmar, CA, 
USA). SU-8 developer (1-methoxy-2-propyl acetate) was acquired from MicroChem (Newton, 
MA, USA). Poly(dimethylsiloxane) (PDMS) (Slygard 184 Silicone Elastomer) was purchased 
from Dow Corning (Midland, MI). 
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3.2.2 Fabrication of a Three-Channel Device for Automated Single-Cell Capillary 
Electrophoresis 
 
The three-channel system for physiologic buffer, air, and electrophoretic buffer was 
fabricated from PDMS (Figure 3.1).33 The channel for loading electrophoretic buffer was 3 cm in 
length, 0.5 cm in width, and 1.5 mm in depth. The physiologic buffer channel was 3.5 x 0.3 cm, 
with circular reservoirs that were 1 cm in diameter at both ends of the channel. The 
electrophoretic and physiologic buffer channels were connected by a perpendicular 5 x 1 mm 
channel that was filled with air. The PDMS channels were bonded to a 1002F-coated coverslip 
containing an array of 10 x 10 microwell cell traps.34 The cell trap array was placed at the center 
of the physiologic buffer channel. The cell traps used to capture K562 and primary cells were 30 
μm and 15 μm in diameter, respectively. All cell traps were 20 μm in depth and separated from 
adjacent traps by 100 μm. The arrays of cell traps were fabricated using standard 
photolithographic procedures. Coverslips were washed with water, ethanol, and then dried using 
nitrogen gas. Coverslips were then plasma-cleaned for 45 min (PDC-001, Harrick), spin-coated 
with 1002F-10 for 30 s at 1100 rpm, and soft-baked for 30 min at 95°C. The 1002F-coated 
coverslip was then covered with an iron oxide photomask and illuminated with a total dose of 
600 mJ of light using a UV exposure system (Oriel, Newport Stratford, Inc., Stratford, CT). The 
photoresist-coated coverslip was subsequently baked at 95°C for 8 min, developed for 2 min in 
SU-8 developer, rinsed with isopropanol, and then hard-baked for 30 min at 120°C. 
3.2.3 Isolation of primary peripheral blood mononuclear cells from whole blood 
De-identified patient peripheral blood samples were obtained from the University of 
North Carolina Hematolymphoid Malignancies Tissue Procurement Facility under an 
institutional IRB-approved protocol in accordance with the Declaration of Helsinki. The Tissue 
 80 
Procurement Facility additionally provided information about the percentage of leukemic cells 
for each patient. Peripheral blood samples were stored at room temperature and processed using 
Ficoll-Paque PLUS density centrifugation within 24 h after extraction. Briefly, 5 mL of Ficoll-
Paque PLUS (GE Healthcare Bio-Sciences, Pittsburgh, PA) was added to a sterile 15 mL 
centrifuge tube (Denville Scientific Inc., Metuchen, NJ). 8 mL of whole blood diluted at least 1:1 
in phosphate buffered saline (PBS) was gently layered on the Ficoll-Paque PLUS, so as not to 
disturb the interface between the liquids. The tubes were centrifuged for 20 min with the brake 
off at 900 x g in a swinging bucket centrifuge. PBMCs were collected from the interface of the 
two layers and immediately washed twice with PBS.  
3.2.4 Cell Culture 
K562 cells, which were derived from a CML patient in blast crisis, were grown in RPMI 
supplemented with 10% FBS, 50 mg/mL streptomycin, and 50 units/mL penicillin. Frozen K562 
cells were thawed and passed for one week before being utilized in single-cell experiments. 
K562 cells were not used in assays past their 15th passage. Primary cells were maintained in 
AIM-V® containing 10% heat-inactivated HS and 1% penicillin/streptomycin. Fresh primary 
cells were analyzed within 6 h of isolation from whole blood. Between experiments, primary and 
cultured K562 cells were stored at 37°C in a humidified incubator with 5% carbon dioxide. 
3.2.5 Cell Viability Measurements 
Viability was determined using a trypan blue exclusion assay. Cells were pelleted, 
resuspended in PBS, and stained with a final concentration of 0.35% trypan blue. Viable cells 
were counted using a hemocytometer 2-3 min after the addition of the trypan blue stain. At least 
100 cells were counted for each viability determination. The number of cells per unit volume of 
buffer was determined by counting viable cells using a hemocytometer. 
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3.2.6 Enrichment of CD34+ Acute Myeloid Leukemic Blasts  
Selection of CD34+ cells from Ficoll-Paque PLUS isolated PBMCs was performed using 
the CD34 MicroBead Kit UltraPure (Miltenyi Biotec, Inc.) following the manufacturer’s 
protocol. To check for purity and viability, the cells were stained with a PE-conjugated anti-
CD34 antibody (555822; BD Biosciences) and DAPI, and then analyzed on a MACSQuant flow 
cytometer (Miltenyi Biotec, Inc.). 
3.2.7 Loading of Sphingosine-Fluorescein into Cells  
For single-cell experiments, SF was loaded into cells by incubating 5 x 105 cells in 100 
μL culture media containing freshly diluted SF for 30 min. SF concentrations of 20 μM and 80 
μM were used for reporter loading in K562 cells and primary cells, respectively. Cells were 
stored at 37°C in a 5% carbon dioxide atmosphere during incubation with SF. Cells were 
pelleted and then washed 5 x with 200 μL physiologic buffer (135 mM sodium chloride, 5 mM 
potassium chloride, 1 mM magnesium chloride, 1 mM calcium chloride, 10 mM HEPES, and 10 
mM glucose at pH 7.4). Cells were then resuspended in physiologic buffer at a concentration of 1 
x 106 cells/mL and immediately loaded into the arrayed cell traps.  
3.2.8 Measurements of Sphingosine Kinase Activity in Peripheral Blood Mononuclear Cell 
Lysates 
 
For ensemble measurements of SK activity, 5 x 105 PBMCs were pelleted and 
resuspended in culture media at a concentration of 5 x 106 cells/mL. The cells were then 
incubated with 80 μM SF for 1 h at 37°C and 5% carbon dioxide. During reporter incubation, 
cells were gently resuspended every 15 min to minimize settling. After 1 h, cells were pelleted, 
washed 5 x with 200 μL physiologic buffer, and resuspended in 10 μL physiologic buffer. Cells 
were lysed by adding 10 μL methanol and stored at -80°C until analysis. Lysate samples were 
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diluted in electrophoretic buffer (27 mM monosodium phosphate and 10% 1-propanol at pH 7.3) 
and analyzed using a custom-built CE system, described previously.33 The sample was separated 
in a 35 cm fused-silica capillary with an inner diameter of 30 μm. The field strength was 450 
V/cm, and laser-induced fluorescence detection was performed 4 cm from the capillary inlet. 
Standards of SF and S1PF were used to identify analyte migration times. Electropherograms 
were analyzed using a multiple peak fit function for Gaussian peaks (OriginPro 8.1, OriginLab, 
Northhampton, MA).  
3.2.9 Capture of Cells in Three-Channel Device 
Prior to the single-cell analysis, the three-channel device containing cell traps was 
mounted on an inverted microscope (Ti-E, Nikon (Melville, NY)) with a computer-controlled 
motorized stage (Ti-SER, Nikon). The stage was fitted with a temperature controlled stage insert, 
maintained at 37°C for the duration of the experiment. The address of each cell trap in the 
microwell array was calculated using a customized Python program (Wolfeboro Falls, NH).33 
Cells loaded with SF reporter were seeded into the microwells by placing 10 μL of a solution of 
cells on the microwell array. After allowing the cells to settle into the cell traps for 5 – 10 min, 
excess cells were rinsed from the array with physiologic buffer. The trapped cells were then 
continually bathed in physiologic buffer at 35°C (1 mm/s flow velocity). Each cell trap with a 
single cell was manually identified and its address input into a customized program for 
subsequent analysis. 
3.2.10 Single-Cell Analysis of Sphingosine Kinase Activity with Capillary Electrophoresis 
 
Automated single-cell analysis was performed as described previously.33 Prior to 
analysis, the inlet of a 35 cm, 30 μm i.d. capillary was manually aligned 50 μm above the plane 
of the microwells. Upon start of the program, the following events occurred sequentially under 
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computer control. The microscope stage moved to the address of the first cell, placing the cell 
directly below the inlet of the capillary (Figure 3.1). The cell was lysed using a focused laser 
pulse35 and 5 kV was applied across the capillary for 1 s to electrokinetically inject the cellular 
contents. The applied voltage was then set to zero for 1 s and the stage was moved to the center 
of the electrophoretic buffer channel. During this stage movement, the capillary was transferred 
through the air gap connecting the electrophoretic and physiologic buffer channel so that the 
alignment of the capillary was not disturbed. In addition, the air gap prevented the physiologic 
and electrophoretic buffers from mixing. Once the capillary was moved into the electrophoretic 
buffer, a voltage of 18 kV was applied across the capillary for 55 s, 56 s, or 57 s to separate the 
cellular contents. The voltage was then set to zero for 1 s during which time the capillary was 
moved back to the physiologic buffer and placed at the address of the next cell to be assayed. 
This process was repeated until all of the cells in the array were analyzed. A Python program 
controlled the motorized stage while all other tasks were performed using customized software 
written in LabVIEW (National Instruments, Austin, TX). Data was analyzed using a custom-
built MATLAB program (Natick, MA).36 Cells with fluorescence values that saturated the PMT 
were omitted from subsequent analysis. 
 
3.3 Results and Discussion 
3.3.1 Characterization of Sphingosine Kinase Activity in Tissue-Cultured Cells of 
Leukemic Origin 
 
In order to characterize system performance using cells of leukemic origin, a tissue-
cultured cell line, K562 (derived from CML), was initially analyzed. K562 cells were incubated 
with SF, washed, and trapped within arrayed microwells prior to analysis by automated CE.33 
The automated CE system was used to sequentially lyse, inject, and separate the contents of 
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single K562 cells in the microwell array (Figure 3.1). Individual K562 cells were analyzed at a 
rate of 0.98 ± 0.07 cell/min, in order to fully separate SF, S1PF, and additional fluorescent 
products without peak overlap from sequentially injected cells. 94 cells were measured over the 
course of five experiments. The resulting electropherograms contained as many as three 
fluorescent peaks (Figure 3.2A). The first peak migrated at 33 ± 2 s, a migration time identical to 
that of SF standards. The second peak co-migrated with standards of S1PF at 45 ± 2 s. The final 
peak, termed U50, was of unknown identity and migrated at 50 ± 2 s. The separation efficiencies 
were 4000 ± 2000, 8000 ± 4000, and 8000 ± 4000 for SF, S1PF, and U50, respectively. The 
resolution was 5.3 ± 1.1 for SF and S1PF and 2.3 ± 0.6 for S1PF and U50. The automated CE 
system enabled fast and efficient separations on these nonadherent cells derived from leukemia.  
In order to characterize SK activity in all of the analyzed K562 cells, a customized 
MATLAB program was developed to identify peaks attributable to each cell and measure their 
migration time, peak area, and full width at half maximum. The peak areas were then compared 
to that of standards of known concentration to estimate the number of moles of SF and S1PF 
found in each cell.36 The number of moles of U50 was estimated by comparing the peak area of 
the U50 peak to the average moles per peak area of SF and S1PF standards. The majority of cells 
(79 ± 30%) formed S1PF, although in varying amounts (Figure 3.2B). The percentage of reporter 
converted to S1PF (S1PFmol/(SFmol+ S1PFmol + U50 mol)) varied from 0% to 100% (Figure 3.2C). 
Distinct subpopulations of cells were not readily identifiable with respect to the percentage of 
S1PF formed. The amount of reporter loaded into the cells varied by as much as four orders of 
magnitude, with an average of 6 ± 14 amol per cell. The percentage phosphorylation of the 
reporter did not correlate with the total amount of reporter loaded into the cell (coefficient of 
determination (R2) = 0.03) or the time after the cell was loaded with SF (R2 = 0.08) (Figure 
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3.3A). Previous research has also indicated that the phosphorylation of the reporter was not 
dependent on the amount of reporter loading or the time after loading.33 This likely indicates that 
the heterogeneity of single-cell SK activity obscures these trends.  
When observed at the single-cell level, the metabolism of SF in K562 cells was 
extremely heterogeneous. The average percentage of the reporter that was phosphorylated in 
K562 cells was 39%. However, only 18% of cells possessed 34 to 44% of the SF in the phospho 
form, and nearly as many cells (17%) had either very high (>95%) or low <5%) levels of 
phosphorylation. Single-cell measurements of SK activity provided a significantly richer picture 
of sphingosine metabolism than that derived from population-averaged data. The distribution of 
SK activity in the K562 cells was quite different from that previously measured in U937 cells, a 
histiocytic lymphoma/sarcoma-derived cell line with myeloid leukemia properties.33 In the U937 
cells, two cell populations were readily observed with respect to SK activity, a high state (>80% 
of SF converted to S1PF) and a low state (<1% of SF converted to S1PF). Most U937 cells 
(78%) existed in the high state, whereas only 9% of K562 cells possessed >80% phosphorylated 
S1PF. Even though both cell lines were derived from aggressive hematologic malignancies, SK 
activity varied greatly between these two cell types. Both cell types did possess cells expected to 
be susceptible to SK inhibitors as well as unresponsive to SK inhibitors.  
The percentage of U50 formed in single K562 cells varied across the cell population by as 
much as that for S1PF. 60% of K562 cells converted SF to U50 and within this population there 
was significant heterogeneity in the percent of the reporter that was converted (Figure 3.2D). The 
average percentage of U50 formed with respect to total reporter for all K562 cells was 12 ± 25%. 
Since U50 was not observed in cells that were not loaded with SF, U50 was most likely formed 
from an unidentified enzyme acting on SF or a downstream metabolite of the SK pathway 
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(Figure 3.4). The identification of U50 awaits synthesis of standards of additional fluorescent 
metabolites of the sphingosine signaling pathway. The number of moles of U50 produced in cells 
was weakly correlated with S1PF (R2 = 0.46), the total amount of SF loaded into the cell (R2 = 
0.26) and the incubation time of the reporter in the cell (R2 = 0.22) (Figure 3.3B-D). The amount 
of U50 produced in cells was more strongly correlated with the amount of S1PF formed rather 
than the total SF loaded into the cell suggesting that U50 might be a downstream product of 
S1PF, such as hexadecenal fluorescein (Figure 3.4). The migration time of U50 also suggested 
that it possessed a more polar chemical structure than SF, which additionally supports the 
hypothesis that it might be a downstream product of S1PF.  
3.3.2 Analysis of Primary Peripheral Blood Mononuclear Cell Populations 
To evaluate the activity of SK in human primary cells, initial experiments focused on the 
suitability of freshly frozen PBMCs from leukemic patients. These PBMCs contain a mixed 
population of mononuclear blood cells, including immature leukemic blasts as well as more 
differentiated tumor cells and normal lymphocytes, monocytes, and macrophages. Frozen 
PBMCs were chosen as a tissue source due to the ready availability of frozen specimens. 
However, frozen primary PBMCs can rapidly lose viability upon thawing.37 Consequently, initial 
experiments focused on identifying the time span over which the cells remained intact as 
determined by trypan-blue exclusion assays. Immediately upon thawing, 94 ± 2% of cells 
excluded trypan blue but this number dropped to 87 ± 2% after 4 h and to 71 ± 1% after 24 h. 
The number of cells in the culture volume also decreased by 69 ± 16% over the first 24 h. These 
data suggested that cells should be assayed immediately after thawing to maximize viability.  
While the frozen primary cells might be viable immediately after thawing, their rapid 
decline over 24 h suggested that the cells may be on a programmed pathway to death and not 
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suitable for use in signaling assays, particularly assays investigating apoptosis. To determine 
whether SK activity was altered by freezing, SK activity was measured in cell lysates prepared 
from fresh or thawed cells from the same leukemic patient. PBMCs were collected from a 
patient, and divided into 2 samples. The first sample was incubated with SF, lysed, and then 
assayed for formation of S1PF. The second sample was frozen for 24 h, thawed, and then 
immediately incubated with SF and lysed. The lysate prepared from frozen cells exhibited 
decreased conversion of SF to S1PF relative to the lysate from fresh cells (0% vs 10% of SF 
converted to S1PF) (Figure 3.5A-B). The freshly prepared lysate also exhibited a number of SF 
metabolite peaks that were not present on the electropherograms obtained from the previously 
frozen cell lysate. Similar results were obtained for K562 cell lysates, in which conversion of the 
SF reporter to S1PF and additional metabolites decreased by 46 ± 24% after being frozen and 
thawed. These data suggest that frozen primary cells (and frozen tissue cultured cells) rapidly 
lose SK activity as well as other related enzymatic activities upon thawing and are not suitable 
for assay of the SK pathway. Therefore, fresh primary cells were used for all subsequent assays.  
3.3.3 Measuring Single-Cell Sphingosine Kinase Activity in Peripheral Blood Mononuclear 
Cells of Patients with Leukemia 
 
In order to characterize the activity of SK in primary samples, PBMCs of leukemic 
patients were isolated from a patient with accelerated phase CML with 5% leukemic blasts (the 
other white blood cells were leukemia-derived but more differentiated), a patient with relapsed 
AML with 87% blasts, and a patient with de-novo B-ALL with 20% blasts. SK activity was then 
measured in freshly isolated cells loaded with SF and without regard for the cell type within the 
sample. A total of 22, 13, and 39 cells from a single CML patient, a single AML patient, and a 
single B-ALL patient were analyzed, respectively. Due to the heterogeneity of the samples, it 
was expected that 1, 11, and 8 of these cells were leukemic blasts, for CML, AML, and B-ALL 
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PBMC samples, respectively. Single-cell traces from each patient are shown in Figure 3.6(A-C). 
All PBMC samples possessed cells with analytes that co-migrated with SF and S1PF. Two cells 
from the CML patient and three cells from the AML patient displayed up to five unidentified 
peaks that were named based on their migration times, U50 (50.6 ± 0.1 s), U53 (53.0 ± 0.2 s), U55 
(54.8 ± 0.1 s), U57 (57.5 ± 0.5 s), and U60 (60.9 ± 0.6 s) (Figure 3.6A). The number of peaks per 
cell varied within each patient, as well as between patients (Figure 3.6D). The total amount of 
reporter per cell varied from 1.7 ± 2 amol to 21 ± 80 amol for the patient samples, but was not 
significantly different between the three patient samples (Table 3.1). These levels are similar to 
endogenous amounts of sphingosine, which ranges from 5 – 30 amol per cell.38,39 The percentage 
of SF converted to S1PF varied considerably among the cells from all three patients (Figure 
3.6E). However, there were too few cells to accurately measure the correlation between the 
amount of S1PF and the reporter loading amount and time (Figure 3.7 and Figure 3.8). In 
contrast to U937 and K562 cells, the majority of PBMCs converted very little SF to S1PF 
(Figure 3.6F). None of the patients had significantly different levels of phosphorylation or 
production of unidentified compounds despite the diverse disease states and dissimilar numbers 
of normal vs tumor cells. These samples demonstrated the challenge of performing 
measurements on patient samples comprised of very small numbers of mixed cell types. A future 
step for this work will be to combine single-cell CE with fluorescence microscopy of 
immunostained cells to distinguish cell types just prior to CE analysis. However, these data do 
demonstrate the ability of the automated CE system to detect fluorescent sphingosine and its 
metabolites in single primary cells.  
3.3.4 Single-Cell Sphingosine Kinase Activity in Isolated CD34+ Acute Myeloid Leukemic 
Blasts  
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In order to characterize SK activity in leukemic blasts, CD34+ leukemic cells were 
isolated from an AML patient. CD34 is a leukemic stem cell marker expressed in a subset of 
AML patients and CD34 expression is linked to poor prognosis.40 An AML patient expressing 
CD34 was identified by flow cytometry of the peripheral blood cells and the CD34+ cells were 
then enriched by positive selection using magnetic-activated cell sorting (Figure 3.9A). The 
enriched cells were then examined by flow cytometry for viability and purity (Figure 3.9B). 92% 
of the cells were judged to be viable using DAPI exclusion, and 99% of the viable cells 
expressed CD34. SK activity was then measured in this purified population of freshly-isolated 
CD34+ leukemic cells.  
  The CD34+ leukemic stem cells differed from the mixed PBMC populations by several 
attributes. The CD34+ cells possessed a ten-fold lower amount of SF relative to the prior samples 
despite being loaded with SF under identical conditions (Table 3.1). CD34+ cells are known to 
express high levels of drug efflux pumps, so the lower amount of SF measured in CD34+ cells 
may be due to higher levels of SF efflux.41,42 Despite containing less SF, the average percent 
phosphorylation per cell was 19 ± 36%, which was comparable to the PBMCs. A total of 18% of 
cells phosphorylated the reporter, at levels from 45% to 100% phosphorylation (Figure 3.9C). 
The percentage of SF converted to S1PF did not correlate with the incubation time for SF within 
the cell (R2 = 0.02) and was not strongly correlated with total SF loaded into the cell (R2 = 0.34) 
(Figure 3.10). SK activity was highly variable when viewed at the single cell level even in this 
relatively pure population of cells from a single patient. Moreover, a minor subpopulation of the 
cells displayed very high SK activity relative to the other cells in the population. These results 
support previous findings that there is immense phenotypic heterogeneity in leukemia,43 and 
 90 
demonstrate that understanding the diversity of SK signaling in single primary cells will be 
important to determine the suitability of SK inhibitors as treatments for leukemia. 
In addition to displaying heterogeneous SK activity, the CD34+ cells also demonstrated 
variable conversion of the reporter to the unidentified peak U50. 27 % of CD34
+ cells contained 
U50, at levels ranging from 23% to 100% of the reporter present (Figure 3.9D-E). The CD34
+ 
cells possessed a significantly higher average percentage of U50 per cell than the mixed PBMCs 
(Table 3.1). Interestingly, there was a greater average percentage of reporter converted to U50 (27 
± 39%) in the CD34+ cells than that for S1PF in any of the primary cells examined. It will be 
important to identify U50 in future studies to understand whether it is a metabolite of S1PF, in 
which case SK inhibitors might still be effective against the U50-generating cells. If U50 is a 
product of enzymes upstream of SK, however, then SK inhibitors would likely not be effective in 
a patient such as this (Figure 3.4). This work, in addition to existing studies,44 demonstrates the 
necessity of fully characterizing multiple signaling pathways at the single-cell level in order to 
identify the best therapeutic targets in individual patients. 
 
3.4 Conclusion 
Measurement of SK activity in primary and immortalized cells of the hematopoietic 
system was optimized. Frozen cells were found to be inferior to fresh samples because freezing 
and thawing resulted in a significant drop in SK activity as well as the activity of other enzymes 
within this pathway. Thus fresh samples are critically important for accurate measurements of 
SK signaling. SK activity was highly variable within single cells from freshly isolated PBMCs. 
Since mixed populations of cells were present in each PBMC sample, the heterogeneity may 
have reflected the diverse cell types within the sample. However, when SK activity was 
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measured in a nearly pure population of leukemic blasts, these cells also demonstrated a 
significant level of heterogeneity in SK activity. The SK pathway was highly active in a 
subpopulation of these CD34+ blasts cells; however, the majority of the cells did not convert 
substantial quantities of SF to other metabolites in the SK pathway. These blasts also generated 
significantly more of the unidentified compound U50 than the tissue cultured cells or the PBMCs. 
A future goal of this work will be identification of the U50 compound and consequently the 
enzyme(s) responsible for converting SF into this metabolite. This may enable identification of 
additional drug targets in leukemic cells.  
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3.5 Figures and Tables 
 
Figure 3.1: Operation of the automated single-cell analysis system. (A) Schematic of the three-
channel device for containing electrophoretic buffer and cell buffer. (B) Schematic of the single-
cell analysis procedure. Cells loaded with SF were trapped in a microwell array constructed 
using 1002F photoresist wells on a glass slide. The capillary was positioned directly over a cell 
(1), the cell was lysed and electrokinetically injected into the capillary (2), and the capillary was 
transferred through the air gap into the electrophoretic buffer (3). The contents of the cell were 
separated in the capillary and the process was repeated (4) by transferring the capillary through 
the air gap and positioning it over the next single cell in the array. 
 93 
 
 
Figure 3.2: SF reporter metabolism in single K562 cells. (A) A representative electropherogram 
of a single-cell experiment in which SF, S1PF, and U50 were separated in 18 K562 cells. (Inset) 
An expanded region of the electropherogram shows the separation of the reporter and its 
metabolites in 3 cells. (B) Percent of phosphorylated reporter (S1PFmol/(SFmol + S1PFmol + U50 
mol)) plotted against the total amount of reporter loaded (SFmol + S1PFmol + U50 mol) into each cell 
(n = 94). (C) The distribution in the percentage of SF phosphorylated in K562 cells. (D) The 
percentage of SF converted to U50 (U50 mol/(SFmol + S1PFmol + U50 mol)) plotted against the total 
reporter loaded into a cell. 
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Figure 3.3: Characterization of S1PF and U50 in K562 cells. (A) Shown is the dependence of % 
phosphorylation (S1PFmol/(SFmol + S1PFmol + U50 mol)) on time in K562 cells. The percent of 
phosphorylation of the reporter was plotted against the time after the reporter was loaded into 
cells. (B-C) Shown is the relationship between the number of moles of U50 formed and the molar 
amount of SF and S1PF, and time in K562 cells. (B) The moles of U50 formed are plotted against 
the total moles of SF initially loaded into cells. (C) The moles of U50 are plotted against the 
moles of S1PF formed in cells. (D) The moles U50 are plotted against the time after the reporter 
was loaded into cells. 
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Figure 3.4: Schematic showing the enzymes in the SK pathway and the metabolites that the SF 
reporter might form in cells.  
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Figure 3.5: Comparison of SF reporter conversion in fresh vs frozen PBMC lysates. (A) An 
electropherogram showing the conversion of the SF reporter to S1PF and several unidentified 
metabolites in a lysate prepared from fresh PBMCs. (B) An electropherogram demonstrating the 
decrease in SF metabolism in a lysate prepared from frozen PBMCs. 
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Figure 3.6: Measurements of reporter metabolism in single PBMCs from three patients with 
different types of leukemia. (A-C) Electrophoretic traces from a CML patient with 5% leukemic 
blasts (A), an AML patient with 87% leukemic blasts (B), and a B-ALL patient with 20% 
leukemic blasts (C). (D) The distribution of the number of electropherogram peaks identified in 
each cell for the different patients. (E) The percent of reporter phosphorylation (S1PFmol/(SFmol + 
S1PFmol + U50 mol + U53 mol + U55 mol + U57 mol + U60 mol)) plotted against the total amount of 
reporter loaded into each cell (SFmol + S1PFmol + U50 mol + U53 mol + U55 mol + U57 mol + U60 mol) for 
each patient. (F) A histogram showing the percentage of S1PF relative to total SF loaded in the 
PBMCs for each patient. 
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Figure 3.7: The percent of phosphorylated SF reporter plotted against the time after the reporter 
was loaded into cells for single PBMCs from the CML, AML, and B-ALL patients.  
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Figure 3.8: The percent of phosphorylated reporter (S1PFmol/(SFmol + S1PFmol + U50 mol)) plotted 
against the total reporter loaded into single PBMCs from the CML, AML, and B-ALL patients.  
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Figure 3.9: Single-cell measurements in CD34+ cells isolated from the PBMCs of an AML 
patient. (A) Flow cytometry data of the PBMCs prior to CD34+ enrichment by MACS. Side light 
scatter (SSC) is plotted against phycoerythrin (PE) fluorescence. The cells were labeled with PE-
-CD34+. (B) Flow cytometry data of the MACS-enriched CD34+ PBMCs. (C) Percent of 
phosphorylated reporter (S1PFmol/(SFmol + S1PFmol + U50 mol)) plotted against the total amount of 
reporter loaded into a CD34+ cell (SFmol + S1PFmol + U50 mol). (D) Histogram showing the 
distribution of reporter phosphorylation and conversion to U50 (U50 mol/(SFmol + S1PFmol + U50 
mol)). (E) The percent of reporter converted to U50 was plotted against the total reporter loaded 
into a cell. 
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Figure 3.10: The percent of phosphorylated SF reporter plotted against the time between reporter 
loading and cell analysis (A) or against the total reporter loaded into the cell (B). The cells were 
single CD34+ enriched leukemic blasts from an AML patient.  
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Table 3.1: Properties of PBMCs and CD34+ cells for the four leukemic patients 
Parameter Averages (per cell) 
Cells 
% 
Blasts 
SF loaded 
(amol) 
Incubation 
time (min) 
% S1PF % U50 
Total number of 
cells assayed 
CML patient 
PBMCs 
5 21 ± 80 171 ± 7 16 ± 25 0.8 ± 2.5 22 
AML patient 
PBMCs 
87 13 ± 20 195 ± 4 11 ± 26 0.8 ± 2.5 13 
B-ALL patient 
PBMCs 
20 1.7 ± 2 185 ± 20 13 ± 23 0 ± 0 39 
AML CD34+ 99 0.12 ± 0.2** 92 ± 20** 19 ± 36 27 ± 39* 45 
 
* p < 0.05; ** p < 0.01  
p values were calculated by comparing all cellular measurements per patient between all 4 
patients 
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CHAPTER 4: ANALYSIS OF SPHINGOSINE KINASE ACTIVITY IN SINGLE 
NATURAL KILLER CELLS FROM PERIPHERAL BLOOD 
 
 
 
4.1 Introduction 
4.1.1 Natural Killer Cells 
 Natural killer (NK) cells are effector lymphocytes that play a vital role in the immune 
response. NK cells can rapidly attack tumor cells and pathogen-infected cells in the absence of 
antigen-specific cell surface receptors.1 Instead, they express major histocompatibility complex 
(MHC) class 1-specific inhibitory receptors, which give them the ability to recognize “self” 
markers. Upon interaction with foreign or stressed cells missing “self” markers, NK cells lose 
these inhibitory signals and become activated. NK cells also express activating receptors, such as 
natural killer group 2, member D (NKG2D), which recognize ligands overexpressed in distressed 
or damaged cells.2 Upon activation, NK cells can release cytotoxic granules capable of inducing 
lysis or apoptosis in target cells. NK cells are also major producers of cytokines, such as tumor 
necrosis factor α (TNF-α) and interleukein-10 (IL-10), which can stimulate either 
proinflammatory or immunosuppressive responses, respectively.3 NK cells are typically grouped 
into two major subsets, CD56bright and CD56dim cells, based on the expression of the surface 
receptor, CD56.4 CD56bright cells represent up to 10% of NK cells in peripheral blood, and are 
generally weakly cytotoxic but very active cytokine producers.5 The remaining 90% of 
peripheral blood NK cells are CD56dim, which are typically more cytotoxic but less efficient 
cytokine producers. However, a recent study employing mass cytometry to perform single-cell 
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analysis using antibodies against 28 NK cell receptors and as 8 lineage markers revealed 
extraordinary phenotypic heterogeneity between primary NK cells.6 The study determined that 
inhibitory receptor expression was primarily determined by genetics, while activating receptors 
were heavily influenced by the environment. Based on these results, the authors estimated that 
there are between 6,000 to 30,000 distinct subsets of NK cells in the peripheral blood of a single 
person.7 This level of heterogeneity demonstrates that each NK cell is likely unique and that 
technologies capable of single-cell measurements are vital to characterizing the physiology and 
function of NK cells.  
4.1.2 Sphingosine Kinase Pathway in Natural Killer Cells  
 The sphingosine kinase (SK) pathway (Figure 4.1A) is a key regulator of lymphocyte 
migration, differentiation, and cytokine production.8,9,10 SK phosphorylates the lipid signaling 
molecule sphingosine to sphingosine-1-phosphate (S1P). Sphingosine can also be acetylated by 
ceramide synthase (CerS) to form ceramide. S1P is degraded to hexadecenal and ethanolamine 
phosphate by S1P lyase (S1PL). S1P drives lymphocyte proliferation, differentiation, blood-
vessel egress, and regulates the production of pro-inflammatory cytokines. Increases in 
sphingosine and ceramide typically act in opposition to S1P and promote inflammation, 
apoptosis, and autophagy.11 Dysregulation of the SK pathway has been linked to a number of 
diseases of the immune system, including autoimmune disease, asthma, rheumatoid arthritis, and 
inflammatory bowel disease. The SK pathway is particularly important for regulating NK cell 
migration and cytotoxicity. Gradients of S1P drive NK cell chemotaxis, and S1PR5, a member of 
the S1P receptor (S1PR) family, is essential for the mobilization of NK cells to inflamed 
organs.12 Despite promoting increased NK cell mobility, S1P has also been shown to inhibit NK 
cell cytotoxicity.13 Conversely, glycosylated ceramides have been shown to enhance NK cell 
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cytotoxicity.14 Understanding the balance between these lipids in NK cells will contribute to a 
better understanding of their role in regulating NK cell function and behavior. However, the 
activities of SK pathway enzymes during normal and abnormal NK-cell physiologic behaviors, 
particularly the activity of the critical enzyme SK, are currently not well described. Measuring 
SK activity in NK cells will therefore reveal important information pertaining to NK cell 
physiology and disease treatment. 
4.1.3 Techniques for Measuring Sphingosine Kinase Activity in Primary Cells 
 Although single-cell measurements are important for characterizing cellular 
heterogeneity in populations such as NK cells, developing the technology capable of direct 
measurements of single-cell lipid enzyme activity in human samples is challenging. This is 
mainly due to the difficulties in measuring enzyme activity directly in primary cells and 
conducting measurements with sufficiently low limits of detection (LODs). Antibodies specific 
to the phosphorylated form of proteins have been successfully used to measure kinase activity in 
single primary cells.15,16 However, antibody assays are frequently confounded by nonspecific 
binding, typically do not measure the relative amounts of enzyme products and substrates, and 
therefore do not measure enzyme activity directly. In addition, developing a direct lipid kinase 
assay using antibodies would be challenging because lipids are poorly immunogenic.17 
Genetically encoded fluorescent fusion proteins have been utilized to assess enzymatic activity in 
single cells, but these reporters are not compatible for use with most primary cells and each 
reporter requires significant effort to design, construct, and validate.18 Sphingosine tagged with a 
fluorophore or in combination with [32P]ATP, can be easily loaded into primary cells, and then 
used to perform measurements of SK activity. However, this requires the physical separation of 
the tagged sphingosine and S1P or radioactive ATP and S1P, which is often done using thin-
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layer chromatography (TLC)19 or high performance liquid chromatography (HPLC).20 HPLC 
with mass spectrometry detection has also been used to measure endogenous sphingolipids in 
cell lysates.21 However, HPLC and TLC do not currently have sufficient limits of detection to 
perform single-cell measurements of sphingosine and its metabolites. Capillary electrophoresis 
(CE) is a separation technique that is routinely used to achieve sub-attomole limits of detection. 
CE can be used to analyze single-cells, a process termed chemical cytometry, and has even been 
used to measure phosphorylation of kinase reporters in single primary cells.22,23,24 Previously, an 
automated CE system was employed to quantify the phosphorylation of a fluorescent 
sphingosine reporter (SF) to fluorescent S1P (S1PF) in hundreds of immune cells.25 The 
automation of this single-cell CE system increased throughput 100-fold compared to that attained 
by non-automated CE systems. The development of the automated CE system has enabled the 
analysis of sufficiently large numbers of human cells to chemically examine the heterogeneity of 
NK cells with respect to the SK pathway.  
 This work will describe the use of automated single-cell CE to characterize the SK 
pathway in single primary human NK cells enriched from peripheral blood. The conversion of 
SF to S1PF was measured in enriched NK cells from four healthy subjects. The activity of S1P 
phosphatase (S1PP) was also assayed in the enriched NK cells of two subjects by loading S1PF 
into cells and measuring its conversion to SF. As sphingosine and S1P are interconvertible, the 
separate analysis of S1PP and SK activity revealed information about the relative activity of 
these two enzymes. In addition, the formation of an unidentified metabolite in the SK pathway 
was characterized. The heterogeneity in SK pathway activity was quantified amongst cells from 
a single subject as well as between different subjects. Measuring the single-cell activities of SK 
and S1PP revealed novel information about the regulation of the SK pathway in NK cells. 
 112 
 
4.2 Experimental Design 
4.2.1 Reagents and Materials 
 Sphingosine 5/6-fluorescein (SF) and sphingosine-1-phosphate 5/6-fluorescein (S1PF) 
were procured from Echelon Biosciences Inc. (Salt Lake City, UT). Monosodium phosphate, 1-
propanol, isopropanol, methanol, and pre-cleaned glass slides (50 mm x 45 mm x 1.5 mm) were 
acquired from Fisher Scientific (Pittsburgh, PA). Sodium chloride, sodium azide, potassium 
chloride, paraformaldehyde, magnesium chloride, calcium chloride, piperazine-1-ethanesulfonic 
acid (HEPES), and glucose were purchased from Sigma-Aldrich Inc. (St. Louis, MO). Ethanol 
was procured from Decon Labs (King of Prussia, PA). Roswell Park Memorial Institute Media 
(RPMI) with L-glutamine, fetal bovine serum (FBS), Dulbecco’s phosphate buffered saline, and 
penicillin/streptomycin were purchased from Invitrogen (Grand Island, NY). EPON resin 1002F 
(phenol, 4,4’-(1-methylethylidene) bis-, polymer with 2,2’-[(1-methylethylidene) bis (4,1-
phenyleneoxymethylene)]bis-[oxirane]) was acquired from Miller-Stephenson (Sylmar, CA, 
USA). SU-8 developer (1-methoxy-2-propyl acetate) was purchased from MicroChem (Newton, 
MA, USA). Poly(dimethylsiloxane) (PDMS) (Slygard 184 Silicone Elastomer) was procured 
from Dow Corning (Midland, MI). 
4.2.2 Natural Killer Cell Enrichment 
 Blood was drawn from study participants using a protocol approved by the University of 
North Carolina Institutional Review Board for Biomedical Research. Written consent was 
provided by each study participant. Peripheral blood mononuclear cells (PBMCs) were isolated 
using a Lymphoprep gradient (Axis Shield, Scotland, United Kingdom), similar to that used in 
previous studies.26-28 NK cells were isolated from PBMCs using Dynabeads NK isolation kit 
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(Invitrogen, Carlsbad, CA). After isolation, the NK cells were resuspended in media (RMPI 1640 
with L-glutamine, 10% heat-inactivated FBS, and 1% penicillin/streptomycin) for single-cell 
analysis or flow buffer (1% heat-inactivated FBS and 0.09% sodium azide in Dulbecco’s 
phosphate buffered saline without magnesium or calcium) for flow cytometry analysis. 
4.2.3 Flow Cytometry  
 NK cells were incubated with CD45-APCCy7 (BD Biosciences, San Jose, CA) and 
CD56-PE (BD Biosciences), as in previous studies.26-28 The cells were fixed in 0.5% 
paraformaldehyde, and analyzed within 24 hours of fixation by flow cytometer (BD LSRII, BD 
Biosciences). Data were analyzed with FLOWJO (TreeStar, Ashland, OR). 
4.2.4 Fabrication of Microwells 
 The arrays of 10 x 10 microwell cell traps (Figure 4.1B-C) were fabricated by patterning 
holes into a photoresist layer on a coverslip using standard photolithography as described 
previously.25 Briefly, coverslips were spin-coated with 1002F photoresist, and baked at 95 °C for 
30 min.29 An iron oxide photomask was then placed above the 1002F-coated coverslip and the 
assembly illuminated with UV light (600 mJ). The photoresist-coated coverslip was subsequently 
developed in SU-8 developer, rinsed with isopropanol, and then baked at 120 °C for 30 min. The 
microwells or cell traps were 20 μm in depth and separated from adjacent wells by 100 μm. 
4.2.5 Fabrication of Poly(dimethylsiloxane) Channel System.  
The PDMS channel system used to store the captured cells in a physiologic buffer 
solution as well as to contain the electrophoretic buffer for CE separations was similar to that 
described previously.25 A PDMS layer with cutouts for the physiologic and electrophoretic-
buffer channels was bonded to the microwell array (Figure 4.1C-D). The electrophoretic-buffer 
channel was parallel to the physiologic buffer-channel. These buffer channels were connected by 
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a perpendicular channel filled with air. The electrophoretic and physiologic buffers remained in 
their respective channels due to surface tension. The cell trap array was placed in the physiologic 
buffer channel aligned with the center of the air-channel.  
4.2.6 Reporter Loading  
For single-cell experiments, SF and S1PF were loaded into cells by incubating 5 x 105 
cells in 100 μL NK cell media containing 80 μM SF or S1PF for 30 min at 37 °C in a 5% carbon 
dioxide atmosphere. For cell lysate experiments, cells were incubated with 10 μM SF for 1 h. 
After reporter loading, cells were pelleted and then washed 5 times with 200 μL physiologic 
buffer (135 mM sodium chloride, 5 mM potassium chloride, 1 mM magnesium chloride, 1 mM 
calcium chloride, 10 mM HEPES, and 10 mM glucose at pH 7.4). For single-cell experiments, 
cells were then resuspended in physiologic buffer at a concentration of 1 x 104 cells/μL and 
immediately loaded into cell traps. For cell lysate experiments, cells were resuspended in 10 μL 
of physiologic buffer and then chemically lysed by adding 10 μL of methanol. Cell lysates were 
immediately stored at -80 °C until analysis. Statistical differences in reporter loading with SF vs 
S1PF were calculated using a Mann-Whitney U-Test.30 
4.2.7 Ensemble Measurements of the Sphingosine Kinase Pathway Using Cell Lysates  
 
 Two types of cells were used to perform analysis of SK activity in cell lysates: PBMCs 
enriched for NK cells and tissue-cultured K562 cells originally derived from a chronic 
myelogenous leukemia patient. SK activity was measured in both cell types by loading cells with 
reporter, as described above, lysing the cells, and separating the fluorescent compounds using CE. 
For experiments testing the effect of SK inhibition, K562 cells were incubated in media (RMPI 
1640 with L-glutamine, 10% heat-inactivated FBS, and 1% penicillin/streptomycin) with varying 
concentrations of SK Inhibitor 2 (SKI 2) (Cayman Chemical Co., Ann Arbor, MI) for 30 min.31 
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SF reporter was then added to this media, as detailed above, and SK activity was measured. The 
cells were therefore exposed to SKI 2 for a total period of 1.5 h. In order to test the effects of 
ceramide synthase inhibition, K562 cells were incubated with 10 M fumonisin B1, a ceramide 
synthase inhibitor, for 2 h.32 Cells were then loaded with the reporter, lysed, and analyzed using 
CE. Cells were exposed to fumonisin B1 for a total of 3 h. 
4.2.8 Cell Capture in Microwells  
SF or S1PF-loaded NK cells were captured in microwells by pipetting 10 μL of cells (1 x 
106 cells/mL) onto the microwell array. The cells were incubated on the array for 20 min, and 
then excess cells were rinsed from the array with physiologic buffer. The cells trapped in the 
wells were then continually bathed in physiologic buffer at 35 °C (1 mm/s flow velocity). A 
student t-test was used to compare the capture efficiency of microwells with different diameters. 
4.2.9 Automation of Single-Cell Analysis 
The PDMS channel system was mounted on an inverted microscope (Ti-E, Nikon, 
Melville, NY) with a computer-controlled motorized stage (Ti-SER, Nikon). The microscope 
stage was fitted with a temperature controlled stage insert. The insert was maintained at 37 °C 
for the duration of the experiment. Customized software (Python,Wolfeboro Falls, NH and 
MicroManager, Vale Lab, UCSF) identified the address of each cell trap and moved the 
motorized stage.25 Each cell trap that did not contain a single cell was manually deleted from the 
program’s list of well addresses to be interrogated, so that only wells with single-cells were 
analyzed. All other tasks were performed using LabVIEW (National Instruments, Austin, TX). 
4.2.10 Measurement of Sphingosine Kinase Activity in Single Cells 
During automated single-cell analysis, the following events occurred sequentially under 
computer control. The microscope stage moved to the address of the first cell to be analyzed, 
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placing the cell directly below the inlet of a capillary (30 μm i.d.). The capillary was aligned 50 
μm above the plane of the microwells. A focused laser pulse lysed the cell by creating a 
cavitation bubble33 and the cell’s contents were then electrokinetically loaded into the capillary. 
Electrokinetic injections were performed by the application of 5 kV across the capillary for 1 s. 
The voltage was then set to zero as the stage moved through the air channel to the center of the 
electrophoretic buffer channel. A voltage of 18 kV (0.5 kV/cm) was applied across the capillary 
for 55 ± 10 s to separate the cellular contents. The voltage was then set to zero for 1 s as the 
stage moved back to place the capillary at the address of the next cell to be assayed. The next cell 
was lysed, then injected, and this entire process was repeated until all of the cells in the array 
were analyzed.  
 The capillary was interrogated 4 cm from the inlet end by the focused beam of a fiber-
coupled diode pumped solid state 473 nm laser and the fluorescence of the analytes detected with 
a photomultiplier tube as described previously.34 The analytes were identified by comparison of 
their migration times to that of standards. The peak areas of SF, S1PF, and unidentified 
compounds were calculated using a custom program written in MATLAB (Natick, MA).35 The 
peak areas of known amounts of SF and S1PF standards were used to calculate the molar amount 
of SF and S1PF contained in each cell. A brightfield image of each cell, taken immediately prior 
to the single-cell experiment, was used to measure cell diameter. Linear regressions were 
performed to determine coefficients of determination (R2). A t test was used to determine 
whether correlations were statistically significant.36 
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4.3. Results and Discussion  
4.3.1 Characterization of Natural Killer Cell Enrichment  
For the following analyses, primary NK cells were enriched from human PBMCs. To 
characterize NK-cell enrichment, flow cytometry was performed on the sample from a single 
subject (Figure 4.2). NK cells were identified from their expression of CD45 and CD56 proteins 
(CD45+CD56+)). CD45+CD56+ cells were enriched to a purity of 86%, with 14% contaminating 
CD45+CD56- leukocytes. The contaminating CD45+CD56- leukocytes are comprised of a diverse 
range of cell types, including lymphocytes, monocytes, and macrophages. These results were 
comparable to previously published NK cell enrichments.26-28 
4.3.2 Optimization of Natural Killer Cell Capture in Microwell Traps 
Prior to CE analysis, single NK cells were loaded into cell traps or microwells to fix their 
positions as well as to isolate them from adjacent cells. Since primary NK cells are small (6-7 
μm in diameter) relative to the size of most cultured cells, the optimal microwell size for capture 
of single NK cells was assessed. Microwells (20 m deep) with 4 different diameters (15, 20, 25, 
and 30 μm) were tested for their single-cell capture efficiency. Enriched NK cells were seeded 
on the microwell trap array and permitted to settle into the traps. The array was then washed to 
remove the excess cells. The 15-μm microwells were significantly more effective at trapping 
single NK cells than the 20, 25, and 30-μm diameter wells (Figure 4.3A). The percentages of 
microwells that captured more than one primary cell were 13 ± 13%, 22 ± 5%, 80 ± 20%, and 63 
± 6% for the 15, 20, 25, and 30 μm microwells, respectively. These results are consistent with 
previous work suggesting that microwells approximately double the size of the cells are most 
efficient at single-cell capture.34 Due to their higher efficiency at capturing single cells, cell traps 
with diameters of 15 μm were used to capture cells for all subsequent single-cell CE assays. 
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4.3.3 Measurement of Sphingosine Fluorescein and Metabolites in Single Primary 
Peripheral Blood Mononuclear Cells Enriched for Natural Killer Cells 
 
PBMCs enriched for NK cells were incubated with the SF reporter and then loaded into 
microwell traps. The diameter of each entrapped cell was measured using brightfield microscopy 
and used as a measure of cell size. The cells were then sequentially lysed and separated using the 
automated, single-cell CE system. The peak migration times, heights, areas, and separation 
efficiencies were measured for the fluorescent analytes from each cell (Figure 4.3B-C). Two of 
the peaks observed in the electropherograms were identified as SF and S1PF based on their 
migration times. In addition to SF and S1PF, a third peak was often observed in cells. This peak 
with an unknown identity was named U50 since it migrated at 50 s. The total reporter loaded per 
cell was defined as the sum of the number of moles of SF, S1PF, and U50 (SFmol + S1PFmol + U50 
mol). The “time of lysis” for each cell was defined as the time between the start of the cell 
incubation with SF or S1PF and the time of cell lysis.  
PBMCs enriched for NK cells from 4 healthy subjects were assayed for SK activity. In 
total, 133 cells (49, 32, 31, and 21 cells from subjects 1 – 4, respectively) were examined. The 
electropherograms from 14 ± 13% of the cells (32%, 7%, 35%, and 0% from subjects 1-4, 
respectively) did not possess any fluorescent peaks, suggesting that an insufficient amount of SF 
was loaded into these cells for detection. For the purposes of quantifying enzyme activity, only 
the 111 cells with identifiable fluorescent peaks on their electropherograms were characterized. 
Within these 111 cells, there was no correlation (R2 = 0.009) between the total amount of 
fluorophore/cell and the cell diameter (Figure 4.4). For all subjects, there was also no correlation 
between the amount of reporter loaded per cell and the time of cell lysis (or incubation time of 
the reporter in the cell) (R2 = 0.02). In addition, there was no correlation between the amount of 
moles of S1PF produced and the time of lysis (R2 = 0.01) for the combined cells from all 
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subjects (Figure 4.5A-B). The number of moles of S1PF produced did increase with the total 
amount of reporter loaded into cells (R2 = 0.9). This correlation was statistically significant (p ≤ 
.001) (Figure 4.6). This relationship remained linear, even at very high amounts of loaded 
reporter, indicating that SK was not saturated in these cells. 5%, 0%, 22%, and 0% of cells from 
subjects 1-4, respectively, fully converted the SF reporter to S1PF. 100% of the SF reporter was 
converted in cells with as high as 28 amol of loaded reporter. Over 98% of the SF reporter was 
converted in cells with as high as 196 amol of loaded reporter, which additionally suggested that 
SK was not saturated. This indicated that SK is highly active in subpopulations of these enriched 
NK cells. 
The percent of phosphorylated reporter (S1PFmol/(total reporter)) was highly variable 
amongst the cells from a single patient as well as between patients (Figure 4.7A). On average, 70 
± 16% of cells produced phosphorylated reporter at levels above 0%. The average percent of 
reporter converted to S1PF was 37 ± 36% across all cells from all subjects. When the cells from 
different subjects were compared, there were similarities as well as subtle differences between 
each subject and in comparison to the averaged data from all cells. The percent of 
phosphorylated reporter ranged from 0 – 100% in subject 1 (Figure 4.7B). Although overall, 
there was a broad distribution of phosphorylation between the cells analyzed from subject 1, the 
majority of cells (51%) phosphorylated the reporter less than 20%. In fact, 45% of subject 1’s 
cells possessed less than 10% S1PF. The remaining cells had a fairly even distribution of 
phosphorylated SF, between 20 – 100%. The cells from subject 2 phosphorylated the reporter at 
levels ranging from 0 – 82%. The majority of subject 2’s cells (63%) also had phosphorylation 
levels less than 20%. 43% of the cells from subject 2 produced less than 10% S1PF. Subject 3’s 
cells phosphorylated the reporter from 0 – 100%. Although a significant population of subject 
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3’s cells (26%) produced S1PF at levels less than 10%, the majority of cells (65%) produced 
more than 50% S1PF. In fact, more of subject 3’s cells (30%) produced over 90 – 100% S1PF 
than produced 0 – 10% S1PF. Subject 4 also had a wide, fairly even, distribution of 
phosphorylation, ranging from 0 – 99% S1PF. The majority of subject 4’s cells (57%) produced 
greater than 50% S1PF. 29% and 19% of Subject 4’s cells had less than 10% phosphorylation 
and greater than 90% phosphorylation, respectively. This data suggested that in all subjects, 
PBMCs enriched for NK cells had a wide range of SK activity. Since the SK pathway is 
implicated in the regulation of NK cell migration and cytotoxicity, traits that are known to vary 
substantially between NK cells, this cell-to-cell heterogeneity may be important for the wide 
range of immune functions in which NK cells participate. 
While similarities existed in cellular SK activity between subjects, there were also 
important differences. For example, subjects 1 and 2 both possessed a distribution in SK activity 
per cell skewed towards lower levels of phosphorylation relative to the distributions of subjects 3 
and 4 (Figure 4.7B). For instance, the majority of cells from subjects 1 and 2 had less than 20% 
phosphorylation, while the majority of subject 3 and 4’s cells had greater than 50% 
phosphorylation. Thus, the cells of subjects 3 and 4 possessed a much greater diversity in SK 
activity per cell relative to that of the cells from subjects 1 and 2, in which the major population 
of cells possessed low SK activity. These distinct patterns of SK activity in PBMCs enriched in 
NK cells could arise from a variety of sources. These include the possibility that the NK cells 
were at different purities in each sample. NK cell activity is also known to vary with gender and 
race, among many other factors.37,38 The demographics information for each subject is shown in 
Table 4.1, although the sample size of four subjects is too small to identify causes of variations 
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in the phosphorylation distribution. Further research will identify the sources of this cell 
heterogeneity. 
4.3.4 U50 Production in Peripheral Blood Mononuclear Cells Enriched for Natural Killer 
Cells 
 
To further investigate U50 and understand how it might be related to SF, the percentage of 
SF converted to U50 was measured for each cell. U50 was produced in 30 ± 10% of cells, at levels 
ranging from less than 1% to 97%. The average percent of reporter converted to U50 was 12 ± 
19% in the cells that formed U50. Formation of U50 was highly variable at the single-cell level 
(Figure 4.7A). On average, the percentage of SF converted to U50 was less than that converted to 
S1PF. However, 9 of 111 cells formed a higher percentage of U50 than S1PF. Out of these 9 
cells, 8 were from subject 1 and 1 was from subject 4. The majority of cells from all four 
subjects displayed low levels of reporter conversion to U50 (Figure 4.7C). 73%, 93%, 83%, and 
81% of cells from subjects 1-4 had less than 5% production of U50, respectively. 16%, 0%, 0%, 
and 0% of the cells from subjects 1-4 had greater than 25% conversion to U50. Due to the 
heterogeneity of the PBMCs analyzed, it is possible that NK cells were not responsible for 
conversion of the reporter to U50. It may be that the ~14% of contaminating leukocytes produced 
the majority of U50 in the PBMCs enriched for NK cells. Overall, these results suggested that U50 
is produced in these NK-enriched PBMCs at lower levels than S1PF. These results provide 
additional evidence that the SK pathway varies between subjects.  
The identity of U50 has important implications in the regulation of NK cells. If U50 is a 
product of ceramide synthase, and/or other enzymes upstream of SF, the subpopulation of cells 
with higher U50 production may be geared towards enhanced apoptosis, cytotoxicity, and 
inflammation. Conversely, if U50 is formed downstream of S1PF, cells producing U50 may have 
even higher SK activity since a significant fraction of the S1PF might have been converted to 
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U50. In that case, the U50-containing cells might have increased proliferation, migration, and 
cytokine production. For these reason, it will be important to identify U50. Intriguingly, there is 
no correlation between the distribution of S1PF and U50 formation between subjects. Subjects 1 
and 2 had similar patterns of reporter phosphorylation, but distinct patterns of U50 formation. 
This suggests that there are additional layers to the regulation of the SK pathway in immune cells 
and simultaneous measurements of the activity of multiple enzymes in this pathway may be 
required to fully understand its role in these cells.  
4.3.5 Identification of U50 
To investigate the identity of U50, K562 cells, which have previously been shown to form 
relatively large amounts of U50, were treated with inhibitors of SK pathway enzymes.
24 
Inhibition of ceramide synthase by fumonisin B1 did not affect the production of U50 in cells 
(Figure 4.8). However, inhibition of SK by SKI 2 was found to decrease formation of U50 in 
addition to production of S1PF (Figure 4.9A). In addition, increasing concentrations of SKI 2 
decreased U50 formation in a dose-dependent manner (Figure 4.9B). This suggested that U50 is 
likely a metabolite downstream of S1PF. For instance, U50 could potentially be fluorescein-
tagged hexadecenal. However, there are presently no commercially available fluorescein-tagged 
standards of S1PL metabolites, such as hexadecenal, so the identity of U50 and its relative 
location in the SK pathway could not be confirmed. A future goal is to synthesize fluorescein-
tagged standards of ceramides, hexadecenal, and other SK pathway metabolites in order to 
confirm the identity of unknown fluorescent compounds. Despite the constraint of its unknown 
identity, the characterization of U50 did provide information about the relative activities of SK 
pathway enzymes, which enabled insight into the SK pathway heterogeneity in PBMCs enriched 
in NK cells. 
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4.3.6 Sphingosine-1-Phosphate Phosphatase Activity in Peripheral Blood Mononuclear 
Cells Enriched for Natural Killer Cells 
 
In order to better characterize the flow of metabolites in the SK pathway, S1PF was 
loaded into cells and its fluorescent metabolites were measured. A total of 41 cells were analyzed 
with 11 from subject 5 and 31 from subject 6. On average, significantly less S1PF reporter (0.2 ± 
0.2 amol) was loaded into cells compared to that for the SF reporter (13 ± 35 amol) (p = 2 x 10-
6). S1PF is more polar than SF, potentially creating an added barrier to traversing the 
membrane.39 17 ± 15% of cells did not load a detectable quantity of S1PF. The amount of S1PF 
reporter loaded did not correlate with the cell diameter for the combined cells from subjects 5 
and 6 (R2 = 0.04) or for the cells for each subject individually (Figure 4.10A). This suggested 
that the uptake of the reporter was not dependent on cell size. The amount of reporter loaded was 
linearly correlated with the time that the reporter was incubated in the cell for both subjects (R2 = 
0.6). This correlation was significant for all cells (p < 0.001), as well as for the cells from 
subjects 5 (p < 0.05) and 6 (p < 0.001), respectively (Figure 4.10B). This relationship may be 
due to slower cellular internalization of the S1PF reporter, due to its enhanced polarity or to a 
different mechanism of import into the cell. The majority of cells (95 ± 8%) that did load S1PF 
did not convert it to any other compounds (Figure 4.10C). None of the cells dephosphorylated 
the reporter to form SF. This suggests that the majority of enriched NK cells analyzed had very 
low S1PP activity, especially in comparison to SK activity. 0% and 11% of S1PF-loaded cells 
from subject 5 and 6, respectively, were observed to convert the reporter to U50. Since both S1PP 
and the U50-producing enzyme(s) have low activity, on average, these data suggested that U50 is 
formed as a metabolite in the S1P/hexadecenal arm of the pathway, i.e. that U50 is likely 
downstream of SK. The low number of cells that converted S1PF to U50 (5 ± 8% in S1PF-loaded 
cells vs 35 ± 10% in SF-loaded cells) may be due to subject variability or to differences in 
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cellular location of S1PF produced from SF and S1PF loaded into the cells externally. Overall, 
this data suggested that in the PBMCs enriched for NK cells, SK activity is much greater than 
that of S1PP. These results further indicate that SK plays a major role in regulating the balance 
between sphingolipid metabolites in peripheral blood NK cells.  
 
4.4 Conclusion 
 Our findings suggest that SK activity and sphingosine metabolite formation is 
heterogeneous in PBMCs enriched for NK cells from a single human as well as between 
different humans. Certain patterns of SK activity distribution were present amongst subjects, 
some displaying biases towards lower SK activity levels per cell and other individuals displaying 
cells with a very broad range of SK activity/cell. Based on the very low levels of back 
conversion of S1PF to SF, S1PP activity in human subjects appears to be significantly lower than 
that of SK activity suggesting that the sphingosine-ceramide pathway in healthy humans is wired 
to rapidly metabolize sphingosine to sphingosine-1-phosphate. The rapid conversion into 
sphingosine-1-phosphate would then act to favor cell proliferation and cell egress out of blood 
vessels into tissue as well as production of pro-inflammatory cytokines. All of these attributes 
would result in rapid activation of the immune system toward pathogens. The formation of an 
additional metabolite in the SK pathway, termed U50, may be the result of S1PF metabolism by 
one or more enzymes, further suggesting that this pathway is poised for rapid immune cell 
activation. These results demonstrated that multiple SK pathway enzymes in PBMCs enriched 
for NK cells possessed heterogeneous activity at the single-cell level, as well as between 
subjects. These results are consistent with the large number of NK cell types thought to be 
present in a single human.4,12 This work also demonstrates the power and reliability of the 
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automated single-cell CE technology. Overall, hundreds of primary cells from six different 
subjects were analyzed. As the throughput of the system and the availability of fluorescent 
sphingolipid reporters are improved, it will be possible to simultaneously analyze the activity of 
multiple kinases and lipases in thousands of cells per human. This will further elucidate the role 
of sphingolipids in NK cell biology and immune-system diseases. 
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4.5 Figures and Tables 
 
Figure 4.1: Schematic of the SK pathway and the device for single-cell analysis. a) SK pathway 
in NK cells. Abbreviations: ceramidase (CDase), ceramide synthase (CS), and S1P lyase (S1PL). 
b) Brightfield image of 6 cell traps. The top middle trap is empty and the other traps contain 
captured PBMCs enriched for NK cells. c) Schematic of a cross section through the microwell 
array loaded with cells (green spheres). d) Schematic of the fluidic channels for automated 
single-cell CE analysis.  
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Figure 4.2: Flow cytometry analysis of PBMCs enriched for NK cells.  
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Figure 4.3: Characterizing and optimizing single-cell analysis of peripheral blood NK cells. a) 
The percent of microwells entrapping a single cell is shown for microwells of varying diameter. 
Three replicates were obtained for each histogram. *p ≤ 0.05 **p ≤ 0.01. b) Representative 
electropherogram demonstrating separation of SF, S1PF, and U50 in 19 cells. c) An expanded 
region of the electropherogram shown in panel b. 
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Figure 4.4: The total reporter loaded into cells (SFmol + S1PFmol + U50 mol) was plotted against the 
diameter of the cell (n = 111).  
 130 
a)        
60 80 100 120
0.01
0.1
1
10
100
 1
 2
 3
 4
T
o
ta
l 
R
e
p
o
rt
e
r 
L
o
a
d
e
d
 (
a
m
o
l)
Time of Cell Lysis (min)
Subject
 
b) 
60 80 100 120
0
20
40
60
80
100
Subject
 1
 2
 3
 4
%
 P
h
o
s
p
h
o
ry
la
ti
o
n
Time of Cell Lysis (min)
 
Figure 4.5: Effect of reporter time in the cell on the amount of reporter loaded and the percentage 
converted to S1PF. a) The total reporter loaded into cells ((SFmol + S1PFmol + U50 mol) and b) the 
percent phosphorylation of the reporter (S1PF/(SFmol + S1PFmol + U50 mol)) were plotted against 
time of cell lysis after cells were loaded with reporter.  
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Figure 4.6: The total amount of S1PF per cell was plotted against the total reporter loaded into 
the cell (SFmol + S1PFmol + U50 mol). The line of complete conversion highlights cells that 
converted 100% of the loaded reporter to S1PF.  
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Figure 4.7: SK activity in PBMCs enriched in NK cells. a) A 3D plot comparing the percentage 
of SF converted to S1PF and U50 to the total concentration of reporter (x axis) loaded into the 
cell (SFmol + S1PFmol + U50 mol). b) Histograms expressing the number of cells with different 
percentages of S1PF for each subject. c) Histograms comparing the percent of reporter converted 
to U50 between all subjects. 
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Figure 4.8: The percent of SF, S1PF, and U50 in cell lysates incubated with a phosphate-buffered 
saline vehicle control or 10 M fumonisin B1, a ceramide synthase inhibitor, for 3 h. There was 
no statistically significant difference between the control cells and the fumonisin-treated cells 
(n=3). 
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Figure 4.9: SK inhibition decreases formation of U50. a) The percent of SF, S1PF, and U50 in cell 
lysates treated with a DMSO vehicle control or with 2 M SK Inhibitor 2 (SKI 2) for 1.5 h (n = 
3). b) The percent of S1PF and U50 formed in cell lysates was plotted against the concentration of 
SKI 2 (n = 3).  
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Figure 4.10: S1PF loading and metabolism in PBMCs enriched in NK cells from two subjects (n 
= 36). a) The total amount of S1PF loaded into cells (S1PFmol + U50 mol) plotted against the 
diameter of the cells. b) The total amount of S1PF loaded into cells (S1PFmol + U50 mol) was 
plotted against the time of cell lysis. c) A 3D graph showing the percent of S1PF and U50 in cells 
plotted against the total amount of S1PF reporter loaded into the cell.  
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Table 4.1: Demographic information for six subjects 
 
Subject Gender Race Age BMI 
1 Male White 33 33.1 
2 Male White 39 28.2 
3 Male White 25 - 
4 Female Asian 24 19.3 
5 Male White 31 22.7 
6 Female White 23 23.1 
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CHAPTER 5: A LIPID BLOCKING TREATMENT FOR ENABLING SINGLE-CELL 
LIPID ENZYME ACTIVITY MEASUREMENTS IN COMPLEX SAMPLES USING 
AUTOMATED CAPILLARY ELECTROPHORESIS 
 
 
 
5.1 Introduction 
5.1.1 The Role of Phospholipase C and Sphingosine Kinase in Leukemia 
Many lipids, which were originally thought to be relatively passive biomolecules, play 
critical roles in modulating signaling pathways.1 For example, sphingolipids in the sphingosine 
kinase (SK) pathway (Figure 5.1A) regulate key cellular processes including apoptosis, 
proliferation, and migration.2 SK, which phosphorylates sphingosine to sphingosine-1-phosphate 
(S1P), is known to be upregulated in a number of cancers, including leukemia.3-5 Inhibitors of 
SK have been shown to kill cancerous cells from AML patients as well as multi-drug resistant 
tissue-cultured leukemic cell lines.6 Phospholipase C (PLC), which irreversibly hydrolyzes 
phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol triphosphate 
(IP3), regulates another important lipid signaling pathway (Figure 5.1B).
7 PIP2, DAG, and IP3 
modulate a range of cell functions including cytokinesis, proliferation, and intracellular calcium 
release. PLC is a downstream signaling molecule for hundreds of growth factor receptors, which 
are often upregulated in cancer.8 Inhibition of PLC has been shown to decrease cancer cell 
motility and formation of tumor metastases.10 Targeting PLC, therefore, is a promising strategy 
to inhibit multiple growth factor receptor pathways simultaneously in a patient’s tumor.9 
However, further studies are needed to elucidate differences in the role of the PLC pathway in 
leukemic vs normal cells to better optimize therapeutics. Therefore, the ability to measure lipid 
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signaling, especially in the PLC and SK pathways, in primary leukemic and normal cells could 
enable the development of novel cancer therapies.  
5.1.2 Importance of Single-Cell Measurements in Complex Samples 
 Heterogeneity is a characteristic feature of leukemia. Patient-to-patient variations in 
kinase activity and gene expression have made it very difficult to develop universally effective 
drugs for treatment of AML, the deadliest form of leukemia.11,12 As a result, the standard 
chemotherapeutic treatment for AML has not been substantially changed for over 40 years.13 In 
addition, there is significant cellular heterogeneity in AML arising partially due to a leukemic 
stem cell (LSC) hierarchy.14 LSCs are thought to be the leukemic equivalent of hematopoietic 
stem cells due to their capacity for self-renewal, proliferation, and differentiation.15 Mature 
leukemic blasts, in comparison, are predominantly post-mitotic and have limited proliferative 
capacity. Thus, finding ways to specifically target small populations of leukemic stem cells for 
cancer therapy would be highly beneficial to prevent tumor repopulation. In fact, LSCs are 
highly resistant to current AML chemotherapeutics, and are thought to be responsible for the 
majority of AML relapses.16,17 Measuring single-cell lipid kinase activity, such as SK and PLC, 
in leukemic stem cells would therefore be significantly more informative than studying those 
pathways in bulk cell lysates. Single-cell analysis of SK and PLC could be used to develop 
therapeutics specifically designed to kill the cells responsible for proliferation and drug 
resistance in AML. 
5.1.3 Methods of Measuring Lipid Enzyme Activity in Single Cells 
 Traditionally, lipid enzyme activity is measured using thin-layer chromatography (TLC). 
In TLC, the lipid substrates, such as sphingosine or PIP2 are physically separated from the 
products of the enzyme reaction, such as S1P or DAG, respectively.18,19 The lipid products S1P 
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and DAG are typically labeled radiometrically or detected using a charring agent, respectively. 
However, these methods have very high limits of detection (LODs) in the nmol range, which 
preclude single-cell analysis. High performance liquid chromatography (HPLC), a 
chromatographic technique with lower limits of detection and higher resolution than TLC, has 
also been used to measure lipid enzyme activity.20 For instance, HPLC was used to separate and 
quantify sphingolipids extracted from human tissue that had been fluorescently derivatized.21 
However, typical LODs for HPLC analysis of lipids are in the pmol range, which are still orders 
of magnitude too high for single-cell analysis. Microscopy and flow cytometry are techniques 
that have been used extensively for single-cell analysis. Both can be used to characterize enzyme 
activity by assaying antibody-binding to specific enzyme states or products of enzymatic 
reactions. For example, phospho-flow cytometry uses antibodies specific for the phosphorylated 
states of kinases and has been used to characterize millions of primary leukemic cells.22 
However, these assays typically do not report direct measurements of enzyme activity because 
the relative levels of enzyme substrate and product are not measured. Additionally, developing 
specific antibodies to lipids is notoriously problematic.23 Antibody assays are also limited to 
examining a single biological compound of interest and, therefore, cannot be used to characterize 
downstream or off-target reactions.  
 Single-cell capillary electrophoresis (CE), a chemical cytometry technique, has been used 
to directly measure the activities of lipid enzymes, including SK and PLC.24,25 An automated 
single-cell CE system has even been used to measure SK activity in dozens of primary cells from 
leukemic patients.26 This was accomplished by loading cells with a fluorescent sphingosine 
reporter (SF) that could be phosphorylated into fluorescent S1P (S1PF) by active SK. A three-
channel device enabling cell capture and rapid exchange between physiologic and 
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electrophoretic buffer was used to perform automated single-cell CE (Figure 5.1C). 24 The device 
was composed of poly(dimethylsiloxane) (PDMS) channels bonded to a photoresist-coated glass 
slide. On the device, single cells were captured in microfabricated cell traps, bathed continuously 
in physiologic buffer, and sequentially lysed, injected into the capillary, and separated using CE. 
The relative amounts of SF and S1PF were used to calculate SK activity. In these experiments, 
nonspecific adsorption of the SF reporter to the surface of the three-channel device caused a 
highly fluorescent background when the SF was loaded into cells already on the device. 
Therefore, the cells had to be pre-loaded with the reporter prior to capture in the microwell array, 
which increased the lag time between reporter loading and single-cell analysis to over an hour. 
Additionally performing immunofluorescence analyses of the cells prior to single-cell CE 
required immunofluorescence staining after SF loading. This further increased the lag time 
between reporter loading and cell analysis to 2-3 h. These long lag times: 1) increased the 
difficulty of measuring similar time points between different patients, 2) prevented analysis of 
kinase activity at time points on the order of minutes, as opposed to hours, and 3) enabled the 
cells to efflux much of the loaded reporter, thereby decreasing the amount of reporter in cells 
over time. In addition, the adsorption of fluorescent lipid reporters, including the fluorescent PIP2 
reporters used to measure PLC activity, was a challenge when using other device substrates 
compatible with cellular assays. Preventing lipid adsorption to the device would enable facile 
coupling of immunofluorescence microscopy to single-cell lipid analysis, allowing the 
characterization of individual cells based on their surface markers and their lipid enzyme 
activity. This would enable measurements of SK and PLC activity in specific subpopulations of 
leukemic cells, such as immature AML cells, which would be highly beneficial for developing 
treatments targeted towards the leukemic stem cells.  
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5.1.4 Measuring Phospholipase C and Sphingosine Kinase Activity in Single Cells 
Identified in Complex Samples Using Immunofluorescence Microscopy 
 
 This chapter will detail a strategy for blocking fluorescent lipid adsorption to the three-
channel device for automated single-cell CE device. Different chemical and biomolecule 
blocking agents were tested for their ability to decrease the adsorption of SF and a fluorescent 
PIP2 reporter. Successful blocking treatments were optimized to further decrease nonspecific 
adsorption of the fluorescent lipid reporters. The efficacy of an optimized blocking treatment was 
tested using a mock single-cell assay. The length of time that lipid adsorption was efficiently 
blocked following treatment was characterized. The effects of the blocking treatments on SK and 
PLC activity were assayed in leukemic cells to determine whether the blocking agent itself might 
alter cellular signaling pathways. This work advances the development of a method for coupling 
immunofluorescence microscopy with automated CE. It also has broader implications, as 
nonspecific biomolecule adsorption is a challenge for many types of biological assays.27  
 
5.2 Experimental Design 
5.2.1 Reagents and Materials 
Sphingosine 5/6-fluorescein (SF), sphingosine-1-phosphate 5/6-fluorescein (S1PF), and 
bodipy fluorescein phosphatidyl inositol 4,5-bisphosphate (PIP2-BF) with a 6 carbon acyl chain 
length were purchased from Echelon Biosciences Inc. (Salt Lake City, UT). 
Phosphoethanolamine (PEA), poly-D-lysine, palmitic acid, collagen, and phosphocholine 
chloride (PCCl) were procured from Sigma-Aldrich Inc. (St. Louis, MO). Bovine serum albumin 
(BSA) was acquired from Calbiotech (Spring Valley, CA). Phosphatidylinositol 4,5-
bisphosphate diC16 (PIP2) was purchased from Echelon Biosciences Inc. 1,2-dihexanoyl-sn-
glycero-3-phosphocholine (DHPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) 
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(POPG), egg phosphatidylcholine (PC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC), 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-3-
trimethylammonium-propane (DMTAP), 1,2-stearoyl-3-trimethylammonium-propane (18:0 
TAP) and dimethyldioctadecylammonium (DDAB) were purchased from Avanti Polar Lipids, 
Inc. (Alabaster, AL). Structures for all blocking agents are shown in Figure 5.2. Sodium chloride, 
potassium chloride, magnesium chloride, calcium chloride, piperazine-1-ethanesulfonic acid 
(HEPES), and glucose were acquired from Sigma-Aldrich Inc. Monosodium phosphate, 1-
propanol, methanol, chloroform, isopropanol, and pre-cleaned glass slides (50 mm x 45 mm x 
1.5 mm) were procured from Fisher Scientific (Pittsburgh, PA). Ethanol was acquired from 
Decon Labs (King of Prussia, PA). Roswell Park Memorial Institute Media (RPMI) was 
purchased from Cellgro (Manassas, VA), fetal bovine serum (FBS) was purchased from Atlanta 
Biologicals (Lawrenceville, GA), and penicillin/streptomycin from Gibco (Grand Island, NY). 
EPON resin 1002F (phenol, 4,4’-(1-methylethylidene) bis-, polymer with 2,2’-[(1-
methylethylidene) bis (4,1-phenyleneoxymethylene)]bis-[oxirane]) was procured from Miller-
Stephenson (Sylmar, CA, USA). SU-8 developer (1-methoxy-2-propyl acetate) was acquired 
from MicroChem (Newton, MA, USA). Poly(dimethylsiloxane) (PDMS) (Slygard 184 Silicone 
Elastomer) was purchased from Dow Corning (Midland, MI). 
5.2.2 Fabrication of the Poly(dimethylsiloxane)-Photoresist Channel System  
 
 The three-channel device for automated single-cell CE was composed of a 
microfabricated array of 15 μm diameter microwells for capturing individual cells (Figure 5.1C). 
The array was located in a poly(dimethylsiloxane) (PDMS) channel designed to contain 
physiologic buffer. A parallel channel contained electrophoretic buffer, which enables high 
resolution CE separations. The two parallel channels were connected by an empty perpendicular 
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channel, or air gap, and the electrophoretic and physiologic buffers remained in their respective 
channels due to surface tension. The electrophoretic buffer channel was 3 cm in length, 0.5 cm in 
width, and 1.5 mm in depth. The physiologic buffer channel was 3.5 x 0.3 cm, with circular 
reservoirs that were 1 cm in diameter at both ends of the channel. The air gap was 5 x 1 mm. The 
PDMS channel system was fabricated using standard soft lithography and was bonded to a 
1002F-coated coverslip containing a microfabricated array of 10 x 10 microwell cell traps. The 
traps were placed at the center of the physiologic buffer channel, in line with the air gap. The cell 
traps were 15 μm in diameter, 20 μm in depth, and separated from adjacent traps by 100 μm. To 
fabricate the cell trap array, coverslips were washed with water, ethanol, and then dried using 
nitrogen gas. Coverslips were then plasma-cleaned for 45 min (PDC-001, Harrick), spin-coated 
with 1002F-10 for 30 s at 1100 rpm, and soft-baked for 30 min at 95°C. The 1002F-coated 
coverslip was then covered with an iron oxide photomask and illuminated with a total dose of 
600 mJ of light using a UV exposure system (Oriel, Newport Stratford, Inc., Stratford, CT). The 
photoresist-coated coverslip was subsequently baked at 95°C for 8 min, developed for 2 min in 
SU-8 developer, rinsed with isopropanol, and then hard-baked for 30 min at 120°C. For a 
number of experiments described in this work, it was only necessary to perform characterization 
using the physiologic buffer channel. For those experiments, the same fabrication procedures 
described above were utilized, but the PDMS channel system was cut to only include the 3.5 x 
0.3 cm physiologic buffer channel, not the air gap and electrophoretic buffer channels. 
5.2.3 Cell Culture 
Jurkat cells, tissue-cultured cells originally derived from a patient with acute T-cell 
leukemia, were grown in RPMI supplemented with 10% FBS, 50 mg/mL streptomycin, and 50 
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units/mL penicillin. Jurkat cells were stored at 37°C in a humidified incubator with 5% carbon 
dioxide.  
5.2.4 Lipid Blocking Assays 
PEA, poly-D-lysine, palmitic acid, collagen, PCCl, BSA, PIP2, DHPC, POPG, PC, 
POPC, DLPC, 18:0 TAP, DMTAP, and DDAB were tested as blocking agents for preventing 
lipid adsorption to the PDMS-1002F device. Devices were prepared by bonding four separate 
PDMS physiologic buffer channels (3.5 x 0.3 cm x 1.5 mm channels without the connecting air 
gap and electrophoretic buffer channel) to a 1002F coated glass slide. Each blocking agent was 
dissolved in a compatible solvent, listed in Table 5.1, at a concentration of 1 mg/mL. The 
PDMS-1002F physiologic buffer channels were plasma-treated for 30 minutes, and then a 
blocking agent solution was immediately added to three of the channels. Physiological buffer 
(135 mM sodium chloride, 5 mM potassium chloride, 1 mM magnesium chloride, 1 mM calcium 
chloride, 10 mM HEPES, and 10 mM glucose at pH 7.4) was added to the fourth channel as a 
control. The channels were then incubated for 1 h at 37°C and 80% relative humidity. After the 1 
h incubation, the solutions were removed from all four channels, which were then washed twice 
with 100 μL of physiologic buffer. The channels were then incubated with fluorescent lipid 
reporters freshly diluted in physiologic buffer. For testing agents for blocking PIP2-BF, 100 μM 
of PIP2-BF was diluted 1:1 with 100 μM histone H1 carrier, incubated for 10 min in the dark at 
room temperature, and then diluted to a final concentration of 1 μM PIP2-BF in physiologic 
buffer. For testing SF blocking, a solution of 10 μM SF diluted in physiologic buffer was 
utilized. Channels were treated with fluorescent lipids for 20 min at 37°C and 80% relative 
humidity. The fluorescent lipid solutions were then completely removed from the channels. The 
channels were then washed twice with 100 μL of physiologic buffer. This step removed all of the 
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fluorescent lipids in solution, leaving only fluorescent lipids that had adsorbed to the PDMS-
1002F channels. 150 μL of electrophoretic buffer (27 mM monosodium phosphate and 10% 1-
propanol at pH 7.3) was added to each channel to dissolve the adsorbed fluorescent lipids.  The 
electrophoretic buffer was then collected and analyzed using CE.  
5.2.5 Capillary Electrophoresis 
Samples were separated in a 35 cm fused-silica capillary with an inner diameter of 30 
μm. Gravity loading was used to inject samples into the capillary. The field strength during 
separations was 450 V/cm, and laser-induced fluorescence detection was performed 4 cm from 
the capillary inlet. Standards of PIP2-BF, SF, and S1PF were used to identify analyte migration 
times. Electropherograms were analyzed using a multiple peak fit function for Gaussian peaks 
(OriginPro 8.1, OriginLab, Northhampton, MA). 
5.2.6 Characterizing the Efficacy of Blocking Treatments 
The blocking efficiency of each agent was analyzed by comparing the amount of 
fluorescent lipid in the electrophoretic buffer wash, collected at the end of the lipid blocking 
experiments. The fluorescent compounds present in each electrophoretic buffer wash were 
analyzed using CE. The relative amounts of fluorescent lipid reporters were determined by 
measuring their peak areas from the resulting electropherograms. The peak areas of either PIP2-
BF or SF in the electrophoretic buffer wash from the lipid blocking agent treated channels were 
normalized to that of the untreated channel (the channel treated with physiologic buffer) for each 
blocking treatment.  
5.2.7 Mock Single-Cell Assay 
 The mock single-cell assay was performed using the same conditions as a single-cell CE 
assay, except in the absence of cells. The three-channel device was attached to an automated 
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microscope stage. The physiologic buffer channel was filled with 1 μM PIP2-BF diluted in 
physiologic buffer. This solution was incubated in the channel for 20 min, and then the PIP2-BF 
solution was then removed, and the channels were washed five times with physiologic buffer. A 
continuous physiologic buffer flow (1 mm/s flow velocity) was applied to the channel for the 
duration of the experiment. A capillary was aligned 50 μm above the plane of the microwells and 
positioned directly over an empty microwell. A focused laser pulse was fired to mimic the cell 
lysis process,28 5 kV was applied across the capillary for 1 s to electrokinetically inject 
physiologic buffer, and the capillary was transferred to the electrophoretic buffer channel. 
Separation and detection of the fluorescent compounds in the physiologic buffer were performed 
as described above. 
5.2.8 Measuring the Effect of Blocking Treatment on Sphingosine Kinase Activity in Cell 
Lysates 
 
PDMS-1002F physiologic buffer channels were washed with ethanol and stored in a 
sterile tissue-culture hood. The channels were then either left untreated or were treated with 
sterile blocking agents in accordance with the optimized protocol. Once the channels were 
treated, they were washed 2 times with 100 μL physiologic buffer. Then, 5 x 105 Jurkat cells in 
100 μL physiologic buffer were added to the channel and incubated for designated times at 37°C 
and 5% carbon dioxide. The cells were immediately loaded with reporter by diluting a 1 mM SF 
solution in the physiologic buffer for a final concentration of 10 μM SF. The cells were then 
incubated with SF reporter for 1 h. The cells were subsequently removed from the PDMS-1002F 
channels, centrifuged at 800g for 3 min, washed 5 x with physiologic buffer, and resuspended in 
10 μL of physiologic buffer. The cells were then lysed by adding 10 μL of methanol, and then 
immediately stored at -20 °C prior to analysis by CE. 
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5.3 Results and Discussion 
5.3.1 Comparing Chemical Treatments for Blocking Fluorescent Lipid Adsorption 
 In order to identify a treatment capable of preventing the adsorption of the PLC reporter 
PIP2-BF, which is fluorescently tagged PIP2 with acyl chain length of six carbons, to the PDMS-
1002F device, the device was treated with a wide range of potential blocking agents prior to 
PIP2-BF incubation. Each treatment was then compared to determine the most effective at 
blocking PIP2-BF adsorption (Figure 5.3A). Several treatments, including PEA, poly-D-lysine, 
and palmitic acid actually increased the binding of PIP2-BF to the surface of the device. The 
most effective treatments were lipids with C6-C18 hydrocarbon chains and polar head groups. The 
amphiphilic nature of these lipids appeared to be important in blocking PIP2-BF, as palmitic acid, 
a highly hydrophobic molecule, did not prevent PIP2-BF adsorption. More polar molecules, such 
as PEA, also were unsuccessful as blocking agents. It is possible that amphiphilic lipids were the 
most effective blocking agents because they were able to bind to both hydrophobic and 
hydrophilic regions of the PDMS and 1002F surfaces. PDMS has a primarily hydrophobic 
surface composed of organosilanes, but can be made more hydrophilic upon plasma treatment, 
which generates silanol groups. The surface of 1002F is predominantly hydrophobic in character 
but also displays more hydrophilic alcohols. DMTAP, a C14 lipid with a quaternary ammonium 
cation head group, blocked relatively more PIP2-BF adsorption than any other treatment. This 
could be due to the cationic head group, which may have assisted DMTAP binding to negative 
charges present on the 1002F and PDMS surface, in addition to binding to the hydrophobic 
surfaces. Due to its efficacy at blocking PIP2-BF adsorption, DMTAP was used to optimize a 
PIP2-BF blocking treatment. 
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 A number of similar treatments were also compared in order to find an effective 
treatment at blocking SF adsorption (Figure 5.3B). SF was more challenging to block than PIP2-
BF. Eight of the ten tested treatments, including a number of treatments that were capable of 
blocking PIP2-BF, increasing SF adsorption compared to an untreated channel. DMTAP, which 
was effective at blocking PIP2-BF, had little to no effect on preventing SF adsorption. DDAB, a 
more hydrophobic (C18) lipid with a quaternary ammonium cation head group was the only 
treatment tested that successfully blocked SF binding. SF may have been harder to block relative 
to PIP2-BF because it is more hydrophobic. This may have enabled it to interact with more 
hydrophobic surface regions compared to PIP2-BF. DDAB, which is more hydrophobic than 
DMTAP, was potentially able to quench these interactions more thoroughly. DDAB was selected 
for further development of a blocking treatment for SF. 
5.3.2 Optimization and Characterization of Lipid Blocking Treatments 
 In order to increase the efficacy of blocking treatments for PIP2-BF and SF, the plasma 
treatment time of the device and the concentration of the blocking treatment were optimized. All 
channels were plasma treated for 4 min to bond the PDMS and 1002F. The channels were then 
allowed to equilibrate for 24 h, and then plasma treated again immediately prior to DMTAP 
treatment. Decreasing the second plasma treatment time was found to increase the blocking 
efficacy of the DMTAP treatment for PIP2-BF (Figure 5.4). The optimal condition was no 
plasma treatment of the channels. In the absence of a plasma treatment, DDAB was also more 
efficient at preventing SF adsorption, blocking 97.6 ± 0.3% of the SF compared to 67 ± 9% to 
after 30 min of plasma treatment. This suggested that omitting the plasma treatment was optimal 
for both DMTAP and DDAB blocking treatments, potentially because the increased 
hydrophobicity of the channels enabled the blocking treatment to bind more effectively to the 
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device. Further optimization was performed by varying the concentrations of the DMTAP and 
DDAB to compare the effect on blocking PIP2-BF and SF, respectively. For both treatments, 
concentrations of 1 mg/mL were the most effective at blocking the respective lipids (Figure 
5.5A-B). Therefore, a total of 74.1 μg/cm2 of DMTAP and DDAB are required to block the 
adsorption of a 1 μM and 10 μM solution of PIP2-BF and SF, respectively. The optimized 
conditions of no plasma treatment and 1 mg/mL concentration of blocking lipids were used in all 
subsequent experiments. 
 In order to characterize whether the optimized treatment would prevent background 
fluorescence during a potential single-cell assay, the fluorescence intensity of PIP2-BF incubated 
in a DMTAP-blocked or untreated channel was measured during a mock single-cell assay in the 
absence of cells. After the incubation time, PIP2-BF was rinsed from the channel using the 
physiologic buffer and the laser microbeam was fired below the capillary and physiologic buffer 
was injected to imitate the single-cell lysis and injection procedure. Electrophoresis was initiated 
in the capillary and fluorescence detection was applied, as it would be in a single-cell assay 
(Figure 5.6A). In the untreated channel, the electropherogram demonstrated a peak that co-
migrated with PIP2-BF. The signal to noise ratio of the peak was 690. This data indicated that a 
substantial amount of PIP2-BF adsorbed to the surface of the native channel and was desorbed 
into solution during the mock single-cell assay. This demonstrates that the fluorescent 
background created by PIP2-BF adsorption in an untreated channel is sufficiently high to prevent 
accurate measurements of PIP2-BF from cells. The electropherogram corresponding to the 
DMTAP-treated channel revealed a substantial decrease in PIP2-BF fluorescence (Figure 5.6B). 
The signal to noise ratio of a small peak in the electropherogram that co-migrated with PIP2-BF 
was 2.8, less than that typically defined as the limit of detection i.e. S/N of 3. The blocking 
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treatment therefore resulted in a 99.6% decrease in PIP2-BF background fluorescence of a mock 
single-cell assay and eliminated a detectable background signal from PIP2-BF adsorption onto 
the channel surfaces. This indicates that the optimized lipid blocking method is highly successful 
at preventing fluorescent lipid adsorption and minimizing resulting background fluorescence.  
 In order to characterize the longevity of the lipid blocking treatments, devices were 
treated with DDAB and DMTAP and then incubated in physiological buffer for varying lengths 
of time. The amount of SF blocked, relative to a channel treated with physiologic buffer, did not 
significantly change over the course of 24 h (Figure 5.7A). This indicated that DDAB remained 
adsorbed to the channel, and did not desorb back into the physiologic buffer over this time range. 
This suggested that DDAB treatment could be applied up to 24 h prior to single-cell analysis. 
However, the amount of PIP2-BF blocked by DMTAP decreased significantly over a two h 
period (Figure 5.7B). This may have been due to the decreased hydrophobicity of DMTAP, 
compared to DDAB. This may have made DMTAP more soluble in physiologic buffer and 
decreased the blocking efficacy over time. In order to test this, the same experiment was 
performed using a longer chain (C18 compared to C14) version of DMTAP, referred to as 18:0 
TAP. After 3 h of storage time, 18:0 TAP was able to block PIP2-BF with the same efficacy as 
DMTAP at 0 h (99 ± 3% vs 97 ± 1%). This suggested that the increased hydrophobicity of 18:0 
TAP enabled consistent blocking of PIP2-BF for long periods of time, without decreasing the 
blocking efficacy. 
5.3.3 Measuring the Effects of Lipid Blocking Treatments on Sphingosine Kinase Activity 
 
 In order to utilize lipid blocking treatments to perform accurate measurements of enzyme 
activity in single cells, the treatments must not disrupt basal levels of enzyme activity. The most 
effective blocking agents, including DMTAP, DDAB, and 18:0 TAP, are long-chain cationic 
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lipids, often used as transfection agents, which can be cytotoxic at high concentrations.29 Thus, 
high surface densities of these adsorbed lipids might cause cellular stress that could alter 
signaling pathways in the cell, including the SK and PLC pathways.30,31 In order to test whether 
the treatments affected SK activity, phosphorylation of the SF reporter was compared in lysates 
from Jurkat cells incubated in lipid-treated channels and untreated treated channels (Figure 5.8). 
The percent of phosphorylated reporter produced by cells loaded with SF significantly decreased 
upon treatment with DMTAP and 18:0 TAP. This suggested that these treatments inhibited SK 
activity. POPC and PC treatments did not significantly affect the phosphorylation of SF in Jurkat 
cells, which indicates that POPC and PC do not alter SK activity. However, POPC and PC 
treatments were shown to be significantly less effective (p = 0.01 and p = 0.02, respectively) at 
preventing SF adsorption, and actually increased SF adsorption under non-optimized conditions. 
In order to test whether the efficacy of POPC and PC treatments could be increased, the lipids 
were tested for blocking SF using the optimized conditions determined for DDAB and DMTAP. 
In these conditions, POPC and PC treatments had significantly increased blocking efficacy 
compared to non-optimized conditions (p = 0.01 and p = 0.02, respectively), although they were 
still not as effective at blocking SF adsorption than DDAB treatments (Figure 5.9). It will be 
important to develop blocking treatments that can effectively prevent PIP2-BF and SF adsorption 
without altering basal enzyme activity. This may be possible by combining lipid blocking agents 
or by optimizing conditions for lipids that do not inhibit or stimulate signaling pathways. 
Another alternative is to coat the device with biofouling resistant polymers, such as polyethylene 
glycol (PEG). This would require grafting PEG onto the 1002F and PDMS surfaces chemically 
or using vapor-phase deposition, which would be require moderately more complex procedures 
and instrumentation, but PEG has been shown to be biocompatible and adept at preventing a 
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wide range of biomolecules from adsorbing to surfaces.27 Future experiments will continue to 
expand upon the characterization and optimization of these lipid blocking treatments.  
 
5.4 Conclusions 
 Lipid blocking agents that successfully prevented the adsorption of SF and PIP2-BF to the 
surfaces of the PDMS-1002F channels were identified. It was found that cationic long-chain 
lipids were the most effective at preventing fluorescent lipid adsorption. Further optimization of 
plasma treatment time and cationic lipid concentration enabled the development of treatments 
capable of preventing more than 95% of SF and PIP2-BF adsorption. A lipid blocking treatment 
for PIP2-BF was found to eliminate the fluorescent background resulting from PIP2-BF 
adsorption in a mock single-cell CE assay. This indicates that these lipid blocking treatments 
could be an effective way to enable fluorescent lipid reporter loading into cells on chip for 
subsequent single-cell analysis. Treatment with DDAB was found to successfully block SF 
adsorption for up to 24 h. Utilizing a similarly hydrophobic lipid, 18:0 TAP, was found to 
prevent PIP2-BF adsorption for at least 3 h. This indicates that these lipid blocking treatments 
could be utilized to store cells and perform experiments over long periods of time. This could 
enable the coupling of immunofluorescence microscopy and automated single-cell CE. However, 
DDAB and 18:0 TAP, the most effective lipid blocking treatments, were found to inhibit 
phosphorylation of the SF reporter. This suggests that these treatments altered basal SK activity, 
and could prevent accurate analysis of enzyme activity. Therefore, further optimization and 
characterization will be utilized to develop methods capable of blocking SF and PIP2-BF 
adsorption without altering basal enzyme activity. This will enable the coupling of 
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immunofluorescence microscopy and single-cell CE for accurate measurements of SK and PLC 
activity in single leukemic cells. 
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5.5 Figures and Tables 
 
Figure 5.1: Schematics of lipid signaling pathways and three-channel device. A) The SK 
pathway. Abbreviations: ceramide synthase (CerS), ceramidase (CDase), S1P phosphatase 
(S1PP), S1P lyase (S1PL). B) Substrates and products of PLC. C) The three-channel device. 
Abbreviations: electrophoretic buffer (Ep Buffer).
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Figure 5.2: Chemical structures of SF, PIP2-BF, and blocking agents. 
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Figure 5.3: Comparing treatments for blocking adsorption of fluorescent lipids. A) The percent 
of PIP2-BF adsorption blocked, normalized to an untreated channel. B) The percent of SF 
adsorption blocked, normalized to an untreated channel.  This data depicts the average value and 
the error bars show the standard deviation (n = 3). 
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Figure 5.4: Optimization of the plasma treatment time of the PDMS-1002F channels. The effect 
of plasma treatment time of PDMS-1002F channels immediately prior to 1mg/mL of DMTAP 
treatment on the percent PIP2-BF adsorption blocked, normalized to untreated channels. This 
data depicts the average value and the error bars show the standard deviation (n = 3). 
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Figure 5.5: Optimization of blocking treatment concentration. A) The percent of blocked PIP2-
BF, normalized to an untreated channel, plotted against the concentration of the DMTAP 
blocking treatment. B) The percent of blocked SF, normalized to an untreated channel, plotted 
against concentration of DDAB treatment. This data depicts the average value and the error bars 
show the standard deviation (n = 3). 
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Figure 5.6: Electropherograms depicting the laser-initiated release of adsorbed PIP2-BF from the 
channel surfaces during in a mock single-cell assay. A) Untreated channel. The major peak in the 
electropherogram co-migrates with PIP2-BF. B) Channel treated with the optimized DMTAP 
protocol. 
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Figure 5.7: The effect of time on lipid blocking treatments. A) The percent of SF blocked, 
normalized to untreated channels, for DDAB treated channels plotted against the storage time of 
the channels after DDAB treatment. B) The percent of PIP2-BF blocked, normalized to untreated 
channels, for DMTAP treated channels plotted against the storage time of the channels after 
DMTAP treatment. This data depicts the average value and the error bars show the standard 
deviation (n = 3). 
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Figure 5.8: The effect of lipid blocking treatments on SK activity in Jurkat cell lysates. The 
percent of phosphorylation of SF (phospho-SF / (SF + phospho-SF)) in cells incubated treated 
and untreated channels. This data depicts the average value and the error bars show the standard 
deviation (n = 3). 
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Figure 5.9: The percent of blocked SF adsorption in channels treated with lipid blocking agents 
using conditions optimized for DDAB and DMTAP. The percentages of SF blocked are not 
significantly different at a 95% confidence level between these treatments. This data depicts the 
average value and the error bars show the standard deviation (n = 3). 
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Table 5.1: List of solvents used for each blocking treatment. 
 
Blocking Agent Solvent 
PEA Physiologic Buffer 
Poly-D-lysine Physiologic Buffer 
Palmitic acid Ethanol 
Collagen Physiologic Buffer 
PCCl Physiologic Buffer 
BSA Physiologic Buffer 
PIP2 Physiologic Buffer 
DHPC Methanol 
PC - Tris 10 mM Tris, pH 7 
PC - MeOH Methanol 
POPG - Tris 10 mM Tris, pH 7 
POPG - MeOH Methanol 
POPC Methanol 
DLPC Methanol 
18:0 TAP Methanol 
DMTAP Methanol 
DDAB Methanol 
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